Reagenti e strumenti per immunologia, biologia cellulare e biologia molecolare
 
> Doxorubicin (hydrochloride) [25316-40-9]

Doxorubicin (hydrochloride) [25316-40-9]

Stampa Stampa
Entra

Cat# HY-15142-100mg

Size : 100mg

Marca : MedChemExpress

Richiedere ulteriori informazioni

Contatta il distributore locale :


Telefono : +1 850 650 7790

Chlorhydrate de doxorubicine (chlorhydrate d'hydroxydaunorubicine), un antibiotique anthracycline cytotoxique, est un agent de chimiothérapie anticancéreuse. Chlorhydrate de doxorubicine inhibe la topoisomérase, arrêtant ainsi la réplication de l'ADN. Chlorhydrate de doxorubicine réduit la phosphorylation basale de AMPK et de son cible en aval acétyl-CoA carboxylase. Chlorhydrate de doxorubicine induit l'apoptose et l'autophagie.

Doxorubicin hydrochloride (Hydroxydaunorubicin hydrochloride), ein zytotoxisches Anthracyclin-Antibiotikum, ist ein Chemotherapeutikum gegen Krebs. Doxorubicinhydrochlorid hemmt die topoisomerase II und stoppt so die DNA-Replikation. Doxorubicin-Hydrochlorid reduziert die basale Phosphorylierung von AMPK und seiner nachgeschalteten Ziel-Acetyl-CoA-Carboxylase. Doxorubicinhydrochlorid induziert apoptosis und autophagy.

Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Doxorubicin hydrochloride Chemical Structure

Doxorubicin hydrochloride Chemical Structure

CAS No. : 25316-40-9

This product is a controlled substance and not for sale in your territory.

Based on 441 publication(s) in Google Scholar

Other Forms of Doxorubicin hydrochloride:

  • Doxorubicin-13C,d3 Obtenir un devis
  • Doxorubicin Obtenir un devis
  • Doxorubicin hydrochloride (Standard) Obtenir un devis

    Doxorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 Nov 25;10(12):887.  [Abstract]

    Doxorubicin or CPT-11 significantly promoted KRT8 expression in chordoma cells in vitro. Western blotting analysis and quantification of KRT8 protein expression (normalized to GAPDH expression).

    Doxorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 Nov 25;10(12):887.  [Abstract]

    Doxorubicin or CPT-11 significantly promoted KRT8 expression in chordoma cells in vitro. Representative images of immunofluorescence staining of KRT8 of CM318 and UCH1 cell line.

    Doxorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2019 Jan;130:557-567.  [Abstract]

    Representative pictures of Live/Dead staining of effects of 7,8-DHF on high dose of Dox-induced cell death and MMP reduction of H9c2 cells.

    Doxorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2019 Sep;23(9):6034-6047.  [Abstract]

    Effects of YWPC (50 mg/L for 24 h) on DOX (5 μM for 24 h)-induces dissipation of mitochondrial membrane potential measured in H9C2 cells loaded with JC-1 using fluorescence microscopy.

    Doxorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2018 Oct 8;9(1):4139.  [Abstract]

    One hour after treated with UV or 2 h after treated with MMS, Camptothecin (CPT) (10 μM), or Doxorubicin (DOX; 0.5 μM), HEK293T cells expressing HA-SUMO2 and His-RhoB are subjected to sumoylation assay to detect the SUMO2 conjugation of RhoB.

    Doxorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2018 Jan 2;128(1):483-499.  [Abstract]

    Immunoblotting for EZH2 in lysates of immortalized mouse podocytes after treatment with Adriamycin (300 ng/mL) for 48 hours (n=6).

    Doxorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2018 Sep 19;37(1):232.  [Abstract]

    Immunoblotting shows that both P-gp protein expression is significantly decreased in 24 h after US exposure in MCF-7/ADR and HEPG2/ADM cells.

    Doxorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Nanoscale Res Lett. 2018 Nov 3;13(1):350.  [Abstract]

    HY-15142

    Doxorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Cell Signal. 2017 May 1;36:108-116.  [Abstract]

    PAQR3 affects DNA damage repair. AGS cells are treated with different doses of VP-16 (for 24 h), CDDP (for 24 h) and Doxorubicin (for 10 h) as indicated, followed by immunoblotting with the antibodies.

    Doxorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Cell Physiol Biochem. 2017;42(3):965-973.  [Abstract]

    U937 cells are treated with Thapsigargin (TG, 1 μM), NSC 125973 (PTX, 5nM) as well as Doxorubincin (DOX, 1 μM) for 12 hours and the indicated proteins are detected by Western blot.

    Doxorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Med. 2016 May;22(5):547-56.  [Abstract]

    Immunofluorescent staining for α-actinin (ACTN2) and cardiac troponin T (TNNT2) to demonstrate sarcomeric organization in hiPSC–CMs derived from patients who do not experience Doxorubicin–induced cardiotoxicity (DOX) versus those who do experience Doxorubicin-induced cardiotoxicity (DOXTOX) after 24 h treatment with Doxorubicin. Scale bar, 20 µm.

    Voir tous les produits spécifiques à Isoform Topoisomerase:

    Voir toutes les isoformes
    Topoisomerase Topo I Topo II

    Voir tous les produits spécifiques à Isoform ADC Cytotoxin:

    Voir toutes les isoformes
    Auristatin Calicheamicins Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

    Voir tous les produits spécifiques à Isoform AMPK:

    Voir toutes les isoformes
    NUAK1 NUAK2 AMPK AMPK α1β1γ1 AMPK α2β1γ1 AMPK α1β2γ1 AMPK α2β2γ1

    Voir tous les produits spécifiques à Isoform HIV:

    Voir toutes les isoformes
    HIV HIV-1 HIV-2

    Voir tous les produits spécifiques à Isoform Antibiotic:

    Voir toutes les isoformes
    Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam
    Description

    Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy[1][2][3].

    IC50 & Target[1][2][3]

    Topoisomerase I

    0.8 μM (IC50)

    Topoisomerase II

    2.67 μM (IC50)

    Daunorubicins/Doxorubicins

     

    HIV-1

     

    Cellular Effect
    Cell Line Type Value Description References
    4T1 IC50
    0.8 μM
    Compound: ADR
    Antiproliferative activity against mouse 4T1 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against mouse 4T1 cells measured after 72 hrs by MTT assay
    		[PMID: 30739826]
    518A2 IC50
    0.12 μM
    Compound: 1
    Cytotoxicity against human 518A2 cells after 72 hrs by MTT assay
    Cytotoxicity against human 518A2 cells after 72 hrs by MTT assay
    		[PMID: 20133021]
    518A2 IC50
    0.17 μM
    Compound: 1
    Cytotoxicity against human 518A2 cells after 48 hrs by MTT assay
    Cytotoxicity against human 518A2 cells after 48 hrs by MTT assay
    		[PMID: 20133021]
    518A2 IC50
    0.34 μM
    Compound: 1
    Cytotoxicity against human 518A2 cells after 24 hrs by MTT assay
    Cytotoxicity against human 518A2 cells after 24 hrs by MTT assay
    		[PMID: 20133021]
    647-V IC50
    < 0.068 mg/mL
    Compound: Doxorubicin
    Cytotoxicity against human 647V cells after 24 hrs by MTT assay
    Cytotoxicity against human 647V cells after 24 hrs by MTT assay
    		[PMID: 22142614]
    769-P IC50
    11.5 μM
    Compound: Adriamycin
    Cytotoxicity against human 769-P cells by MTT assay
    Cytotoxicity against human 769-P cells by MTT assay
    		[PMID: 21875764]
    769-P IC50
    11.5 μM
    Compound: Adriamycin
    Cytotoxicity against human 769-P cells by MTT assay
    Cytotoxicity against human 769-P cells by MTT assay
    		[PMID: 20627721]
    786-0 GI50
    0.43 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human 786-0 cells assessed as growth inhibition by SRB assay
    Cytotoxicity against human 786-0 cells assessed as growth inhibition by SRB assay
    		[PMID: 24507920]
    786-0 IC50
    3.1 μM
    Compound: Adriamycin
    Cytotoxicity against human 786-0 cells by MTT assay
    Cytotoxicity against human 786-0 cells by MTT assay
    		[PMID: 21875764]
    786-0 IC50
    3.1 μM
    Compound: Adriamycin
    Cytotoxicity against human 786-0 cells by MTT assay
    Cytotoxicity against human 786-0 cells by MTT assay
    		[PMID: 20627721]
    A 172 IC50
    18.5 μM
    Compound: Adriamycin
    Cytotoxicity against human A172 cells by MTT assay
    Cytotoxicity against human A172 cells by MTT assay
    		[PMID: 25304898]
    A2780 GI50
    < 0.1 μM
    Compound: ADR
    Anticancer activity against human A2780 cells after 48 hrs by SRB assay
    Anticancer activity against human A2780 cells after 48 hrs by SRB assay
    		[PMID: 20557981]
    A2780 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human A2780 cells after 48 hrs by SRB assay
    Cytotoxicity against human A2780 cells after 48 hrs by SRB assay
    		[PMID: 20554354]
    A2780 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B based ELISA
    Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B based ELISA
    		[PMID: 21402478]
    A2780 GI50
    0.16 μM
    Compound: ADR
    Cytotoxicity against human A2780 cells after 48 hrs by SRB assay
    Cytotoxicity against human A2780 cells after 48 hrs by SRB assay
    		[PMID: 20444601]
    A2780 GI50
    0.16 μM
    Compound: ADR
    Cytotoxicity against human A2780 cells by sulforhodamine B method
    Cytotoxicity against human A2780 cells by sulforhodamine B method
    		[PMID: 21459581]
    A2780 GI50
    0.18 μM
    Compound: ADR
    Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21194809]
    A2780 IC50
    0.5 μM
    Compound: Adriamycin
    Cytotoxicity against human A2780 cells after 48 hrs by MTT assay
    Cytotoxicity against human A2780 cells after 48 hrs by MTT assay
    		[PMID: 30137985]
    A2780 IC50
    2.03 μM
    Compound: ADM
    Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35282680]
    A2780 IC50
    2.69 μM
    Compound: ADM
    Antiproliferative activity against human paclitaxel-resistant A2780/TAX cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human paclitaxel-resistant A2780/TAX cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35282680]
    A-375 IC50
    0.73 μM
    Compound: Doxorubicin.HCl
    Cytotoxicity against human A375 cells after 48 hrs by MTT assay
    Cytotoxicity against human A375 cells after 48 hrs by MTT assay
    		[PMID: 23131338]
    A-375 IC50
    17.2 μM
    Compound: Adriamycin
    Cytotoxicity against human A375 cells by MTT assay
    Cytotoxicity against human A375 cells by MTT assay
    		[PMID: 21875764]
    A-375 IC50
    17.2 μM
    Compound: Adriamycin
    Cytotoxicity against human A375 cells by MTT assay
    Cytotoxicity against human A375 cells by MTT assay
    		[PMID: 20627721]
    A-427 IC50
    1.3 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human A-427 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human A-427 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 34176266]
    A549 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    		[PMID: 20554354]
    A549 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B based ELISA
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B based ELISA
    		[PMID: 21402478]
    A549 IC50
    < 1 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 31804070]
    A549 IC50
    0.002 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as decrease in cell viability by MTT assay
    Cytotoxicity against human A549 cells assessed as decrease in cell viability by MTT assay
    		[PMID: 29489361]
    A549 EC50
    0.04 μM
    Compound: doxorubicin HCl
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 12027739]
    A549 IC50
    0.04 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay
    		10.1039/C5MD00289C
    A549 GI50
    0.06 μM
    Compound: doxorubicin hydrochloride
    Antitumor activity against human A549 cells after 72 hrs by SRB assay
    Antitumor activity against human A549 cells after 72 hrs by SRB assay
    		[PMID: 21718029]
    A549 IC50
    0.1 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    		[PMID: 30049584]
    A549 IC50
    0.1 μM
    Compound: ADM
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 28749671]
    A549 IC50
    0.1 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    		[PMID: 25259515]
    A549 IC50
    0.12 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 30222343]
    A549 GI50
    0.13 μM
    Compound: ADR
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21194809]
    A549 IC50
    0.14 μM
    Compound: ADR
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 30006167]
    A549 IC50
    0.16 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    		[PMID: 29407953]
    A549 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth by CCK-8 assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth by CCK-8 assay
    		[PMID: 36583957]
    A549 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 34282909]
    A549 IC50
    0.2 μM
    Compound: Dox
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 26506221]
    A549 IC50
    0.2 μM
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 23806071]
    A549 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 24 hrs by SRB method
    Cytotoxicity against human A549 cells after 24 hrs by SRB method
    		[PMID: 31904949]
    A549 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 24 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 24 hrs by sulforhodamine B assay
    		[PMID: 28418245]
    A549 IC50
    0.29 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 34165979]
    A549 IC50
    0.3 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    		[PMID: 27462726]
    A549 IC50
    0.329 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against Homo sapiens (human) A549 cells after 72 hr by SRB assay
    Antiproliferative activity against Homo sapiens (human) A549 cells after 72 hr by SRB assay
    		10.1007/s00044-012-0443-x
    A549 IC50
    0.329 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    		[PMID: 22748378]
    A549 IC50
    0.33 μM
    Compound: Doxorubicin HCl
    Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by SRB assay
    		[PMID: 24686018]
    A549 IC50
    0.33 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 24686017]
    A549 IC50
    0.33 μM
    Compound: DOX
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    		[PMID: 22574992]
    A549 IC50
    0.4 μM
    Compound: Adriamycin
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
    		[PMID: 35121401]
    A549 IC50
    0.4 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells measured after 72 hrs by CCK8 assay
    Cytotoxicity against human A549 cells measured after 72 hrs by CCK8 assay
    		[PMID: 31117522]
    A549 IC50
    0.41 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay
    		[PMID: 21192108]
    A549 IC50
    0.44 μM
    Compound: Adr
    Cytotoxicity in human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK-8 assay
    Cytotoxicity in human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK-8 assay
    		[PMID: 31184894]
    A549 IC50
    0.481 μM
    Compound: Adr
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    		[PMID: 29182349]
    A549 IC50
    0.5 μM
    Compound: DOX.HCl
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 28445049]
    A549 IC50
    0.54 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 21123066]
    A549 IC50
    0.69 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 34081476]
    A549 IC50
    0.7 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 32293887]
    A549 IC50
    0.78 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 33689875]
    A549 IC50
    0.85 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition by SRB assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition by SRB assay
    		[PMID: 34762434]
    A549 IC50
    0.9 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 34176266]
    A549 IC50
    1.03 μM
    Compound: ADM
    Antiproliferative activity against human A549 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35282680]
    A549 IC50
    1.13 μM
    Compound: ADR
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    		[PMID: 30837097]
    A549 IC50
    1.2 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 34797067]
    A549 IC50
    1.2 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as cell viability inhibition for 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell viability inhibition for 48 hrs by MTT assay
    		[PMID: 33913326]
    A549 IC50
    1.3 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 30137985]
    A549 IC50
    1.3 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 29286660]
    A549 IC50
    1.45 μM
    Compound: ADR
    Antiproliferative activity in human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity in human A549 cells after 48 hrs by MTT assay
    		[PMID: 28570977]
    A549 IC50
    1.65 μM
    Compound: ADR
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 30677614]
    A549 IC50
    1.7 μM
    Compound: ADR
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 33097300]
    A549 IC50
    1.8 μM
    Compound: Adriamycin
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31268321]
    A549 IC50
    12.5 μM
    Compound: ADM
    Antiproliferative activity against human adriamycin-resistant A549/ADR cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human adriamycin-resistant A549/ADR cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35282680]
    A549 IC50
    152 nM
    Compound: Adriamycin
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs in presence of (R)-4-((3,4-dibenzyl-2,5-dioxopiperazin-1-yl)methyl)-N-hydroxybenzamide by alamar blue assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs in presence of (R)-4-((3,4-dibenzyl-2,5-dioxopiperazin-1-yl)methyl)-N-hydroxybenzamide by alamar blue assay
    		[PMID: 31865013]
    A549 IC50
    2.19 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as inhibition of proliferation incubated for 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of proliferation incubated for 72 hrs by MTT assay
    		[PMID: 34237623]
    A549 IC50
    2.3 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 33301677]
    A549 IC50
    2.36 μM
    Compound: Adriamycin
    Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 32485531]
    A549 IC50
    2.8 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 23477504]
    A549 IC50
    2.9 μM
    Compound: Adriamycin
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31117521]
    A549 IC50
    2.9 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 27704808]
    A549 IC50
    23.71 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    		[PMID: 25226363]
    A549 IC50
    255 nM
    Compound: Adriamycin
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue assay
    		[PMID: 31865013]
    A549 IC50
    4.3 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 25304898]
    A549 IC50
    5 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human A549 cells incubated for 48 hrs by MTT assay
    		[PMID: 32394716]
    A549 GI50
    60.3 nM
    Compound: Doxorubicin HCl
    Growth inhibition of human A549 cells after 72 hrs by SRB assay
    Growth inhibition of human A549 cells after 72 hrs by SRB assay
    		[PMID: 22607205]
    A549 GI50
    7.25 mM
    Compound: Adriamycin
    Growth inhibition of human A549 cells after 48 hrs by MTT assay
    Growth inhibition of human A549 cells after 48 hrs by MTT assay
    		[PMID: 32631569]
    A549 GI50
    7.25 μM
    Compound: ADR
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    		[PMID: 20444601]
    A549 GI50
    7.25 μM
    Compound: ADR
    Cytotoxicity against human A549 cells by sulforhodamine B method
    Cytotoxicity against human A549 cells by sulforhodamine B method
    		[PMID: 21459581]
    A549 IC50
    8.5 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 29884536]
    A549/TR IC50
    42.57 μM
    Compound: ADR
    Cytotoxicity against human A549/TAX cells after 72 hrs by MTT assay
    Cytotoxicity against human A549/TAX cells after 72 hrs by MTT assay
    		[PMID: 30677614]
    ACHN GI50
    0.07 μM
    Compound: Adriamycin
    Growth inhibition of human ACHN cells by SRB assay
    Growth inhibition of human ACHN cells by SRB assay
    		[PMID: 36040099]
    ACHN GI50
    0.07 μM
    Compound: Adriamycin
    Cytotoxicity against human ACHN cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human ACHN cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay
    		[PMID: 29878761]
    ACHN GI50
    0.13 μM
    Compound: ADR
    Cytotoxicity against human ACHN cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Cytotoxicity against human ACHN cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 31668073]
    ACHN IC50
    0.17 μM
    Compound: ADR
    Cytotoxicity against human ACHN cells assessed as cell growth inhibition incubated for 48 hrs by SRB method
    Cytotoxicity against human ACHN cells assessed as cell growth inhibition incubated for 48 hrs by SRB method
    		[PMID: 35302779]
    ACHN IC50
    0.26 μM
    Compound: Adriamycin
    Anti-proliferative activity against human ACHN cells by XTT assay
    Anti-proliferative activity against human ACHN cells by XTT assay
    		[PMID: 25442319]
    AG1523 IC50
    0.4 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human AG01523 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human AG01523 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33774342]
    ASPC1 IC50
    < 5 μM
    Compound: Adriamycin
    Antiproliferative activity against human ASPC1 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    Antiproliferative activity against human ASPC1 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    		[PMID: 35586422]
    ASPC1 IC50
    0.2 μM
    Compound: ADM
    Cytotoxicity against human ASPC1 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human ASPC1 cells assessed as reduction in cell viability by SRB assay
    		[PMID: 35993848]
    ASPC1 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human ASPC1 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human ASPC1 cells assessed as reduction in cell viability by SRB assay
    		[PMID: 32840364]
    ASPC1 IC50
    0.3 μM
    Compound: ADM
    Cytotoxicity against human ASPC1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    Cytotoxicity against human ASPC1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    		[PMID: 35380848]
    ASPC1 IC50
    1.6 μM
    Compound: Adriamycin
    Cytotoxicity against human Aspc-1 cells after 72 hrs under normoxic condition by MTT assay
    Cytotoxicity against human Aspc-1 cells after 72 hrs under normoxic condition by MTT assay
    		[PMID: 29656202]
    ASPC1 IC50
    2 μM
    Compound: Adriamycin
    Cytotoxicity against human Aspc-1 cells after 72 hrs under hypoxic condition by MTT assay
    Cytotoxicity against human Aspc-1 cells after 72 hrs under hypoxic condition by MTT assay
    		[PMID: 29656202]
    B16 IC50
    6.4 μM
    Compound: Adriamycin
    Growth inhibition of mouse B16 cells by MTT method
    Growth inhibition of mouse B16 cells by MTT method
    		[PMID: 25611131]
    B16-BL6 EC50
    0.11 μM
    Compound: doxorubicin HCl
    Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay
    Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay
    		[PMID: 12027739]
    B16-BL6 IC50
    0.2 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against mouse B16-BL6 cells assessed as cell viability after 72 hrs by MTT assay
    Antiproliferative activity against mouse B16-BL6 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 11575942]
    B16-F10 GI50
    0.22 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against mouse B16F10 cells assessed as growth inhibition by SRB assay
    Cytotoxicity against mouse B16F10 cells assessed as growth inhibition by SRB assay
    		[PMID: 24507920]
    BALB/3T3 IC50
    1.078 μM
    Compound: Doxorubicin HCl
    Cytotoxicity against Mus musculus (mouse) BALB/3T3 cells after 72 hr by SRB assay
    Cytotoxicity against Mus musculus (mouse) BALB/3T3 cells after 72 hr by SRB assay
    		10.1007/s00044-012-0443-x
    BALB/3T3 IC50
    1.078 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against mouse BALB/3T3 cells after 72 hrs by SRB assay
    Antiproliferative activity against mouse BALB/3T3 cells after 72 hrs by SRB assay
    		[PMID: 22748378]
    BALB/3T3 IC50
    1.08 μM
    Compound: Doxorubicin HCl
    Cytotoxicity against mouse BALB/3T3 cells assessed as cell viability after 72 hrs by SRB assay
    Cytotoxicity against mouse BALB/3T3 cells assessed as cell viability after 72 hrs by SRB assay
    		[PMID: 24686018]
    BALB/3T3 IC50
    1.08 μM
    Compound: DOX
    Cytotoxicity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 24686017]
    Bcap37 IC50
    0.94 μM
    Compound: ADM
    Growth inhibition of human Bcap37 cells after 72 hrs by MTT assay
    Growth inhibition of human Bcap37 cells after 72 hrs by MTT assay
    		[PMID: 25064351]
    Bel-7402 IC50
    0.274 μM
    Compound: ADR
    Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33676300]
    Bel-7402 IC50
    0.274 μM
    Compound: ADR
    Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
    Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
    		[PMID: 30530194]
    Bel-7402 IC50
    0.3 μM
    Compound: Adriamycin
    Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability by SRB assay
    		[PMID: 32840364]
    Bel-7402 IC50
    0.369 nM
    Compound: Adriamycin
    Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 35152092]
    Bel-7402 IC50
    0.4 μM
    Compound: Adriamycin
    Cytotoxicity against human Bel7402 cells after 24 hrs by SRB method
    Cytotoxicity against human Bel7402 cells after 24 hrs by SRB method
    		[PMID: 31904949]
    Bel-7402 IC50
    0.73 μM
    Compound: ADR
    Antiproliferative activity against human Bel7402 incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Bel7402 incubated for 72 hrs by MTT assay
    		[PMID: 31553932]
    Bel-7402 IC50
    0.73 μM
    Compound: ADR
    Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
    Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
    		[PMID: 30006167]
    Bel-7402 IC50
    0.83 μM
    Compound: Adriamycin
    Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 27158140]
    Bel-7402 IC50
    1.732 μM
    Compound: ADR
    Antiproliferative activity against ADR-resistant human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against ADR-resistant human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33676300]
    Bel-7402 IC50
    11.7 μM
    Compound: Adriamycin
    Cytotoxicity against human Bel7402 cells by MTT assay
    Cytotoxicity against human Bel7402 cells by MTT assay
    		[PMID: 25304898]
    Bel-7402 IC50
    128 μM
    Compound: Adriamycin
    Cytotoxicity against human Bel-7402 cells assessed as inhibition of proliferation incubated for 72 hrs by MTT assay
    Cytotoxicity against human Bel-7402 cells assessed as inhibition of proliferation incubated for 72 hrs by MTT assay
    		[PMID: 34237623]
    Bel7402/5-FU IC50
    10.95 μM
    Compound: ADR
    Cytotoxicity against human Bel7402/5-FU cells after 72 hrs by MTT assay
    Cytotoxicity against human Bel7402/5-FU cells after 72 hrs by MTT assay
    		[PMID: 30677614]
    Bel7402/5-FU IC50
    8.36 μM
    Compound: ADR
    Antiproliferative activity against human Bel7402/5-FU incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Bel7402/5-FU incubated for 72 hrs by MTT assay
    		[PMID: 31553932]
    BGC-823 IC50
    < 1 μM
    Compound: Adriamycin
    Cytotoxicity against human BGC823 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    Cytotoxicity against human BGC823 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    		[PMID: 28757067]
    BGC-823 IC50
    < 1.3 μM
    Compound: Adriamycin
    Cytotoxicity against human BGC823 cells by MTT assay
    Cytotoxicity against human BGC823 cells by MTT assay
    		[PMID: 21875764]
    BGC-823 IC50
    0.01 μM
    Compound: Doxorubicin.HCl
    Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay
    Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay
    		[PMID: 23131338]
    BGC-823 IC50
    0.76 μM
    Compound: adriamycin
    Cytotoxic activity against human BGC823 cells by MTT method
    Cytotoxic activity against human BGC823 cells by MTT method
    		[PMID: 25739048]
    BGC-823 IC50
    1.33 μM
    Compound: Adriamycin
    Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay
    Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay
    		[PMID: 21123066]
    BGC-823 IC50
    1.48 μM
    Compound: Adriamycin
    Cytotoxicity against human BGC823 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human BGC823 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 26933756]
    BGC-823 IC50
    1.5 μM
    Compound: Adriamycin
    Cytotoxicity against human BGC823 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human BGC823 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay
    		[PMID: 28206772]
    BT-474 IC50
    3.2 μM
    Compound: Adriamycin
    Antiproliferative activity against human BT474 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human BT474 cells after 72 hrs by CCK8 assay
    		[PMID: 26988802]
    C6 IC50
    0.06 μM
    Compound: ADR
    Antiproliferative activity against rat C6 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against rat C6 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31977207]
    Caco-2 IC50
    0.97 μM
    Compound: Adriamycin
    Cytotoxicity against human Caco2 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human Caco2 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 26933756]
    CCRF-CEM IC50
    0.15 μM
    Compound: Dox
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by Alamar blue assay
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by Alamar blue assay
    		[PMID: 25064348]
    COLO 205 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human COLO205 cells after 48 hrs by sulforhodamine B based ELISA
    Cytotoxicity against human COLO205 cells after 48 hrs by sulforhodamine B based ELISA
    		[PMID: 21402478]
    COLO 205 GI50
    0.13 μM
    Compound: ADR
    Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay
    Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay
    		[PMID: 20554354]
    COLO 205 GI50
    0.14 μM
    Compound: ADR
    Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay
    Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay
    		[PMID: 20444601]
    COLO 205 GI50
    0.14 μM
    Compound: ADR
    Cytotoxicity against human COLO205 cells by sulforhodamine B method
    Cytotoxicity against human COLO205 cells by sulforhodamine B method
    		[PMID: 21459581]
    CWR22R IC50
    < 1 μM
    Compound: Adriamycin
    Cytotoxicity against human 22Rv1 cells by MTT assay
    Cytotoxicity against human 22Rv1 cells by MTT assay
    		[PMID: 20627721]
    CWR22R IC50
    < 1.3 μM
    Compound: Adriamycin
    Cytotoxicity against human 22Rv1 cells by MTT assay
    Cytotoxicity against human 22Rv1 cells by MTT assay
    		[PMID: 21875764]
    DU-145 IC50
    0.21 μM
    Compound: Doxorubicin.HCl
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 30223117]
    DU-145 IC50
    0.52 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 48 hrs by CCK8 assay
    Cytotoxicity against human DU145 cells after 48 hrs by CCK8 assay
    		[PMID: 26945111]
    DU-145 IC50
    0.52 μM
    Compound: Adriamycin
    Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay
    		[PMID: 27643560]
    DU-145 IC50
    0.87 μM
    Compound: Adriamycin
    Antiproliferative activity against human DU145 cells measured after 72 hrs by EZ-Cytox assay
    Antiproliferative activity against human DU145 cells measured after 72 hrs by EZ-Cytox assay
    		[PMID: 31398033]
    DU-145 IC50
    1 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 2 days by automatic ELISA reader system
    Cytotoxicity against human DU145 cells after 2 days by automatic ELISA reader system
    		[PMID: 20392646]
    DU-145 IC50
    1.02 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells incubated from day 2 to day 4 by CCK8 assay
    Cytotoxicity against human DU145 cells incubated from day 2 to day 4 by CCK8 assay
    		[PMID: 26022080]
    DU-145 IC50
    1.19 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    		[PMID: 20093033]
    DU-145 IC50
    1.3 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 3 days
    Cytotoxicity against human DU145 cells after 3 days
    		[PMID: 19954977]
    DU-145 IC50
    1.4 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 4 days by MTT assay
    Cytotoxicity against human DU145 cells after 4 days by MTT assay
    		[PMID: 20619511]
    DU-145 IC50
    1.5 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 4 days by ELISA reader assay
    Cytotoxicity against human DU145 cells after 4 days by ELISA reader assay
    		[PMID: 19939682]
    DU-145 IC50
    1.59 μM
    Compound: Adriamycin
    Antiproliferative activity against human DU145 cells measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human DU145 cells measured after 72 hrs by CCK8 assay
    		[PMID: 27654394]
    DU-145 IC50
    2.47 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 2 days
    Cytotoxicity against human DU145 cells after 2 days
    		[PMID: 21419530]
    DU-145 IC50
    2.54 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells by MTT assay
    Cytotoxicity against human DU145 cells by MTT assay
    		[PMID: 19836231]
    DU-145 IC50
    2.99 μM
    Compound: Adriamycin
    Antiproliferative activity against human DU-145 cells after 72 hrs by EZ-Cytox colorimetric assay
    Antiproliferative activity against human DU-145 cells after 72 hrs by EZ-Cytox colorimetric assay
    		[PMID: 34678573]
    DU-145 IC50
    21.45 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
    		[PMID: 25226363]
    DU-145 IC50
    3.89 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 4 days by CCK-8 assay
    Cytotoxicity against human DU145 cells after 4 days by CCK-8 assay
    		[PMID: 25062006]
    DU-145 IC50
    4.88 μM
    Compound: ADM
    Cytotoxicity against human DU145 cells after 72 hrs by cell counting kit-8 analysis
    Cytotoxicity against human DU145 cells after 72 hrs by cell counting kit-8 analysis
    		[PMID: 29174815]
    ECa-109 cell line IC50
    0.201 nM
    Compound: Adriamycin
    Cytotoxicity against human Eca-109 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human Eca-109 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 35152092]
    H69AR IC50
    15.1 μM
    Compound: ADM
    Cytotoxicity against human H69AR cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human H69AR cells assessed as reduction in cell viability by SRB assay
    		[PMID: 35993848]
    HBL-100 IC50
    0.14 mg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HBL100 cells after 24 hrs by MTT assay
    Cytotoxicity against human HBL100 cells after 24 hrs by MTT assay
    		[PMID: 22142614]
    HCC70 IC50
    1.45 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCC70 cells measured after 72 hrs by Ez-cytox assay
    Antiproliferative activity against human HCC70 cells measured after 72 hrs by Ez-cytox assay
    		[PMID: 31398033]
    HCT-116 IC50
    > 1.25 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    		[PMID: 35586422]
    HCT-116 IC50
    0.0012 μM
    Compound: Adiramycin
    Anticancer activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay
    Anticancer activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 33940466]
    HCT-116 IC50
    0.01 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay
    		10.1039/C5MD00289C
    HCT-116 IC50
    0.06 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 24 hrs by SRB assay
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 24 hrs by SRB assay
    		[PMID: 31436991]
    HCT-116 IC50
    0.1 μM
    Compound: ADR
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 35762988]
    HCT-116 IC50
    0.1 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by SRB assay
    		[PMID: 32840364]
    HCT-116 IC50
    0.16 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 34165979]
    HCT-116 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 34282909]
    HCT-116 IC50
    0.2 μM
    Compound: ADM
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 29985604]
    HCT-116 IC50
    0.2 μM
    Compound: Dox
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 26506221]
    HCT-116 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells after 24 hrs by SRB method
    Cytotoxicity against human HCT116 cells after 24 hrs by SRB method
    		[PMID: 31904949]
    HCT-116 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    		[PMID: 32880456]
    HCT-116 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells after 24 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT116 cells after 24 hrs by sulforhodamine B assay
    		[PMID: 28418245]
    HCT-116 IC50
    0.39 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against Homo sapiens (human) HCT116 cells after 72 hr by SRB assay
    Antiproliferative activity against Homo sapiens (human) HCT116 cells after 72 hr by SRB assay
    		10.1007/s00044-012-0443-x
    HCT-116 IC50
    0.39 μM
    Compound: Doxorubicin HCl
    Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by SRB assay
    Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by SRB assay
    		[PMID: 24686018]
    HCT-116 IC50
    0.39 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay
    		[PMID: 22748378]
    HCT-116 IC50
    0.41 μM
    Compound: ADR
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 30006167]
    HCT-116 IC50
    0.41 μM
    Compound: adriamycin
    Cytotoxic activity against human HCT116 cells by MTT method
    Cytotoxic activity against human HCT116 cells by MTT method
    		[PMID: 25739048]
    HCT-116 IC50
    1.1 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells after 3 days
    Cytotoxicity against human HCT116 cells after 3 days
    		[PMID: 19954977]
    HCT-116 IC50
    1.4 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay
    		[PMID: 28206772]
    HCT-116 IC50
    2.31 μM
    Compound: ADM
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 29232583]
    HCT-116 IC50
    2.9 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 34176266]
    HCT-116 IC50
    3.03 μM
    Compound: Dox
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    		[PMID: 22318158]
    HCT-116 IC50
    4 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells after 4 days by MTT assay
    Cytotoxicity against human HCT116 cells after 4 days by MTT assay
    		[PMID: 20619511]
    HCT-116 IC50
    5 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 27318975]
    HCT-116 IC50
    5 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 26810315]
    HCT-116 IC50
    6.81 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells after 2 days
    Cytotoxicity against human HCT116 cells after 2 days
    		[PMID: 21419530]
    HCT-15 GI50
    0.05 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT15 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay
    		[PMID: 29878761]
    HCT-15 IC50
    0.09 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells after 3 days by CCK8 assay
    Cytotoxicity against human HCT15 cells after 3 days by CCK8 assay
    		[PMID: 26927425]
    HCT-15 GI50
    0.09 μM
    Compound: Adriamycin
    Growth inhibition of human HCT-15 cells by SRB assay
    Growth inhibition of human HCT-15 cells by SRB assay
    		[PMID: 36040099]
    HCT-15 GI50
    0.14 μM
    Compound: ADR
    Cytotoxicity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Cytotoxicity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 31668073]
    HCT-15 IC50
    0.17 μM
    Compound: ADR
    Cytotoxicity against human HCT-15 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method
    Cytotoxicity against human HCT-15 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method
    		[PMID: 35302779]
    HCT-15 IC50
    0.43 μM
    Compound: Adriamycin
    Anti-proliferative activity against human HCT15 cells by XTT assay
    Anti-proliferative activity against human HCT15 cells by XTT assay
    		[PMID: 25442319]
    HCT-15 IC50
    0.47 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells assessed as reduction in cell growth after 72 hrs by CCK8 assay
    Cytotoxicity against human HCT15 cells assessed as reduction in cell growth after 72 hrs by CCK8 assay
    		[PMID: 27484510]
    HCT-15 IC50
    0.51 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT15 cells incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human HCT15 cells incubated for 72 hrs by CCK8 assay
    		[PMID: 29402741]
    HCT-15 IC50
    0.51 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT15 cells after 72 hrs by EZ-CYTOX reagent based assay
    Antiproliferative activity against human HCT15 cells after 72 hrs by EZ-CYTOX reagent based assay
    		[PMID: 30262132]
    HCT-15 IC50
    0.73 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT15 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human HCT15 cells after 72 hrs by CCK-8 assay
    		[PMID: 29510948]
    HCT-15 IC50
    0.74 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT15 cells measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human HCT15 cells measured after 72 hrs by CCK8 assay
    		[PMID: 27654394]
    HCT-15 IC50
    0.74 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT15 cells measured after 72 hrs by EZ-Cytox assay
    Antiproliferative activity against human HCT15 cells measured after 72 hrs by EZ-Cytox assay
    		[PMID: 31398033]
    HCT-15 IC50
    0.94 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
    		[PMID: 28633898]
    HCT-15 IC50
    1 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
    		[PMID: 28068603]
    HCT-15 IC50
    1.08 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
    		[PMID: 27643560]
    HCT-15 IC50
    1.2 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells after 2 days by automatic ELISA reader system
    Cytotoxicity against human HCT15 cells after 2 days by automatic ELISA reader system
    		[PMID: 20392646]
    HCT-15 IC50
    1.21 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells incubated from day 2 to day 4 by CCK8 assay
    Cytotoxicity against human HCT15 cells incubated from day 2 to day 4 by CCK8 assay
    		[PMID: 26022080]
    HCT-15 IC50
    1.23 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells after 48 hrs by CCK8 assay
    Cytotoxicity against human HCT15 cells after 48 hrs by CCK8 assay
    		[PMID: 26945111]
    HCT-15 IC50
    1.28 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
    		[PMID: 28384547]
    HCT-15 IC50
    1.89 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability after 48 hrs by by Ez-cytoX based microplate reader method
    Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability after 48 hrs by by Ez-cytoX based microplate reader method
    		[PMID: 34597897]
    HCT-15 IC50
    136 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT-15 cells after 72 hrs by EZ-Cytox colorimetric assay
    Antiproliferative activity against human HCT-15 cells after 72 hrs by EZ-Cytox colorimetric assay
    		[PMID: 34678573]
    HCT-15 IC50
    2.12 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells after 4 days by ELISA reader assay
    Cytotoxicity against human HCT15 cells after 4 days by ELISA reader assay
    		[PMID: 19939682]
    HCT-15 IC50
    2.59 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells after 4 days by CCK-8 assay
    Cytotoxicity against human HCT15 cells after 4 days by CCK-8 assay
    		[PMID: 25062006]
    HCT-15 IC50
    23 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
    		[PMID: 26988802]
    HCT-15 IC50
    3.76 μM
    Compound: ADM
    Cytotoxicity against human HCT15 cells after 72 hrs by cell counting kit-8 analysis
    Cytotoxicity against human HCT15 cells after 72 hrs by cell counting kit-8 analysis
    		[PMID: 29174815]
    HCT-8 IC50
    < 1 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT8 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    Cytotoxicity against human HCT8 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    		[PMID: 28757067]
    HCT-8 IC50
    21.6 μM
    Compound: ADM
    Antiproliferative activity against human vincristine-resistant HCT-8/VCR cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human vincristine-resistant HCT-8/VCR cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35282680]
    HCT-8 IC50
    3.98 μM
    Compound: ADM
    Antiproliferative activity against human HCT-8 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HCT-8 cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35282680]
    HEK293 IC50
    0.37 μM
    Compound: ADM
    Cytotoxicity against human HEK293 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    Cytotoxicity against human HEK293 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    		[PMID: 30827866]
    HEK293 IC50
    1.22 μM
    Compound: Adriamycin
    Cytotoxicity against HEK293 cells after 4 days by CCK-8 assay
    Cytotoxicity against HEK293 cells after 4 days by CCK-8 assay
    		[PMID: 25062006]
    HEK293 IC50
    4.96 μM
    Compound: Adriamycin
    Antiproliferative activity against HEK293 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against HEK293 cells after 72 hrs by CCK8 assay
    		[PMID: 27643560]
    HeLa IC50
    < 0.068 mg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    		[PMID: 22142614]
    HeLa GI50
    < 0.1 μM
    Compound: ADR
    Growth inhibition of human HeLa cells after 48 hrs by SRB assay
    Growth inhibition of human HeLa cells after 48 hrs by SRB assay
    		[PMID: 28188067]
    HeLa GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 27987486]
    HeLa IC50
    < 0.1 μM
    Compound: Adiramycin
    Cytotoxicity against human HeLa cells by SRB method
    Cytotoxicity against human HeLa cells by SRB method
    		[PMID: 24951333]
    HeLa IC50
    < 1 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    		[PMID: 28757067]
    HeLa IC50
    < 10 μM
    Compound: Adriamycin
    Anticancer activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Anticancer activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35694689]
    HeLa EC50
    0.02 μM
    Compound: doxorubicin HCl
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 12027739]
    HeLa IC50
    0.1 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability by MTT assay
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability by MTT assay
    		[PMID: 29489361]
    HeLa GI50
    0.17 μM
    Compound: DOX HCl
    Growth inhibition against human HeLa cells after 72 hrs by inverted microscopy
    Growth inhibition against human HeLa cells after 72 hrs by inverted microscopy
    		[PMID: 23353738]
    HeLa IC50
    0.18 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 34165979]
    HeLa IC50
    0.3 μM
    Compound: ADM
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 28749671]
    HeLa IC50
    0.31 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 34081476]
    HeLa IC50
    0.31 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 30222343]
    HeLa IC50
    0.43 μM
    Compound: ADM
    Cytotoxicity against human HeLa cells after 2 days by MTT assay
    Cytotoxicity against human HeLa cells after 2 days by MTT assay
    		[PMID: 21821321]
    HeLa IC50
    0.48 μM
    Compound: Adriamycin
    Anticancer activity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Anticancer activity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 32485531]
    HeLa IC50
    0.5 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 32293887]
    HeLa IC50
    0.5 μM
    Compound: Adriamycin
    Growth inhibition of human HeLa cells after 72 hrs by MTT assay
    Growth inhibition of human HeLa cells after 72 hrs by MTT assay
    		[PMID: 26539973]
    HeLa IC50
    0.5 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability by SRB assay
    		[PMID: 27992183]
    HeLa IC50
    0.6 μM
    Compound: adriamycin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 23806071]
    HeLa IC50
    0.6 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 24 hrs by SRB method
    Cytotoxicity against human HeLa cells after 24 hrs by SRB method
    		[PMID: 31904949]
    HeLa IC50
    0.6 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay
    		[PMID: 32880456]
    HeLa IC50
    0.6 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells by SRB assay
    Cytotoxicity against human HeLa cells by SRB assay
    		[PMID: 29407953]
    HeLa IC50
    0.6 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 24 hrs by sulforhodamine B assay
    Cytotoxicity against human HeLa cells after 24 hrs by sulforhodamine B assay
    		[PMID: 28418245]
    HeLa IC50
    0.602 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 35152092]
    HeLa IC50
    0.69 μg/mL
    Compound: Dox
    Cytotoxicity against Homo sapiens (human) HeLa cells assessed as inhibition of cell viability by MTT assay
    Cytotoxicity against Homo sapiens (human) HeLa cells assessed as inhibition of cell viability by MTT assay
    		10.1007/s00044-013-0486-7
    HeLa IC50
    0.71 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 20093033]
    HeLa IC50
    0.72 μM
    Compound: adriamycin
    Cytotoxic activity against human HeLa cells by MTT method
    Cytotoxic activity against human HeLa cells by MTT method
    		[PMID: 25739048]
    HeLa IC50
    0.8 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells measured after 72 hrs by EZ-Cytox assay
    Antiproliferative activity against human HeLa cells measured after 72 hrs by EZ-Cytox assay
    		[PMID: 31398033]
    HeLa IC50
    0.81 μg/mL
    Compound: Dox
    Cytotoxicity against Homo sapiens (human) HeLa cells assessed as inhibition of cell viability by SRB assay
    Cytotoxicity against Homo sapiens (human) HeLa cells assessed as inhibition of cell viability by SRB assay
    		10.1007/s00044-013-0486-7
    HeLa IC50
    0.82 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 3 days by CCK8 assay
    Cytotoxicity against human HeLa cells after 3 days by CCK8 assay
    		[PMID: 26927425]
    HeLa IC50
    0.88 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 48 hrs by CCK8 assay
    Cytotoxicity against human HeLa cells after 48 hrs by CCK8 assay
    		[PMID: 26945111]
    HeLa IC50
    0.88 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay
    		[PMID: 27643560]
    HeLa IC50
    1 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells assessed as inhibition of growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as inhibition of growth incubated for 72 hrs by MTT assay
    		[PMID: 28206772]
    HeLa IC50
    1 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 2 days by automatic ELISA reader system
    Cytotoxicity against human HeLa cells after 2 days by automatic ELISA reader system
    		[PMID: 20392646]
    HeLa IC50
    1.01 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells incubated from day 2 to day 4 by CCK8 assay
    Cytotoxicity against human HeLa cells incubated from day 2 to day 4 by CCK8 assay
    		[PMID: 26022080]
    HeLa IC50
    1.03 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by Ez-cytoX based microplate reader method
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by Ez-cytoX based microplate reader method
    		[PMID: 34597897]
    HeLa IC50
    1.06 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 27318123]
    HeLa IC50
    1.08 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    		[PMID: 19836231]
    HeLa IC50
    1.13 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 4 days by ELISA reader assay
    Cytotoxicity against human HeLa cells after 4 days by ELISA reader assay
    		[PMID: 19939682]
    HeLa IC50
    1.2 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay
    		[PMID: 28384547]
    HeLa IC50
    1.2 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay
    		[PMID: 28068603]
    HeLa IC50
    1.23 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 28222318]
    HeLa IC50
    1.3 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay
    		[PMID: 34176266]
    HeLa IC50
    1.32 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 2 days
    Cytotoxicity against human HeLa cells after 2 days
    		[PMID: 21419530]
    HeLa IC50
    1.35 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 21123066]
    HeLa IC50
    1.36 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells after 72 hrs by EZ-Cytox colorimetric assay
    Antiproliferative activity against human HeLa cells after 72 hrs by EZ-Cytox colorimetric assay
    		[PMID: 34678573]
    HeLa IC50
    1.4 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 29884536]
    HeLa IC50
    1.5 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human HeLa cells incubated for 72 hrs by CCK8 assay
    		[PMID: 29402741]
    HeLa IC50
    1.5 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells after 72 hrs by EZ-CYTOX reagent based assay
    Antiproliferative activity against human HeLa cells after 72 hrs by EZ-CYTOX reagent based assay
    		[PMID: 30262132]
    HeLa IC50
    1.6 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 3 days
    Cytotoxicity against human HeLa cells after 3 days
    		[PMID: 19954977]
    HeLa IC50
    1.7 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay
    		[PMID: 29510948]
    HeLa IC50
    1.7 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells assessed as reduction in cell growth after 72 hrs by CCK8 assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell growth after 72 hrs by CCK8 assay
    		[PMID: 27484510]
    HeLa IC50
    10.1 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 4 days by MTT assay
    Cytotoxicity against human HeLa cells after 4 days by MTT assay
    		[PMID: 20619511]
    HeLa IC50
    2.5 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 27318975]
    HeLa IC50
    2.77 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay
    		[PMID: 28633898]
    HeLa IC50
    231 nM
    Compound: adriamycin
    Cytotoxicity against wild type human HeLa cells by MTT assay
    Cytotoxicity against wild type human HeLa cells by MTT assay
    		[PMID: 16562842]
    HeLa IC50
    25.65 μM
    Compound: adriamycin
    Cytotoxicity against MDR1-G185 overexpressing human HeLa cells by MTT assay
    Cytotoxicity against MDR1-G185 overexpressing human HeLa cells by MTT assay
    		[PMID: 16562842]
    HeLa/Fucci2 IC50
    2 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa/Fucci2 cells assessed as inhibition of cell viability incubated for 3 days by MTT assay
    Antiproliferative activity against human HeLa/Fucci2 cells assessed as inhibition of cell viability incubated for 3 days by MTT assay
    		[PMID: 31848114]
    HEp-2 IC50
    < 1 μM
    Compound: Adriamycin
    Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    		[PMID: 28757067]
    HepG2 IC50
    < 0.068 mg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    		[PMID: 22142614]
    HepG2 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by SRB assay
    Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by SRB assay
    		10.1007/s00044-012-0423-1
    HepG2 IC50
    < 1 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    		[PMID: 28757067]
    HepG2 IC50
    < 1 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 31804070]
    HepG2 IC50
    < 1.3 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 21875764]
    HepG2 IC50
    0.001 μM
    Compound: Adiramycin
    Anticancer activity against human HepG2 cells assessed as inhibition of cell growth by MTT assay
    Anticancer activity against human HepG2 cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 33940466]
    HepG2 IC50
    0.036 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells by SRB assay
    Cytotoxicity against human HepG2 cells by SRB assay
    		[PMID: 29407953]
    HepG2 GI50
    0.04 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    		[PMID: 27598688]
    HepG2 IC50
    0.1 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability by MTT assay
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability by MTT assay
    		[PMID: 29489361]
    HepG2 IC50
    0.24 μM
    Compound: adriamycin
    Cytotoxic activity against human HepG2 cells by MTT method
    Cytotoxic activity against human HepG2 cells by MTT method
    		[PMID: 25739048]
    HepG2 IC50
    0.3 μM
    Compound: DOX.HCl
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 28445049]
    HepG2 IC50
    0.38 μM
    Compound: Adriamycin
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
    		[PMID: 35121401]
    HepG2 IC50
    0.4 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 34176266]
    HepG2 IC50
    0.45 nM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 35152092]
    HepG2 IC50
    0.66 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 33689875]
    HepG2 IC50
    0.67 μM
    Compound: ADM
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 28818459]
    HepG2 IC50
    0.8 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 34081476]
    HepG2 IC50
    0.85 μM
    Compound: ADR
    Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    		[PMID: 30837097]
    HepG2 IC50
    1 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 20627721]
    HepG2 IC50
    1.09 μM
    Compound: Dox
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 22318158]
    HepG2 IC50
    1.11 μM
    Compound: Doxorubicin.HCl
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 23131338]
    HepG2 IC50
    1.2 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 32293887]
    HepG2 IC50
    1.5 μM
    Compound: Adriamycin
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31268321]
    HepG2 IC50
    1.6 μM
    Compound: ADR
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 33097300]
    HepG2 IC50
    1.9 μM
    Compound: Adriamycin
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31117521]
    HepG2 IC50
    10.1 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 25304898]
    HepG2 CC50
    127 μM
    Compound: ADR
    Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay
    Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay
    		[PMID: 26675440]
    HepG2 IC50
    2.08 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 21144747]
    HepG2 IC50
    2.21 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells assessed as inhibition of proliferation incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of proliferation incubated for 72 hrs by MTT assay
    		[PMID: 34237623]
    HepG2 IC50
    2.32 μM
    Compound: ADM
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 30739827]
    HepG2 IC50
    2.5 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 26810315]
    HepG2 IC50
    2.6 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31013087]
    HepG2/Adm IC50
    144.35 μM
    Compound: ADM
    Cytotoxicity against human HepG2/ADM cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2/ADM cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 28818459]
    HFL1 IC50
    2.31 μM
    Compound: Adriamycin
    Antiproliferative activity against HFL1 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against HFL1 cells after 72 hrs by CCK8 assay
    		[PMID: 27643560]
    HL-60 IC50
    0.01 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 15387667]
    HL-60 IC50
    0.016 μM
    Compound: ADR
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 26832219]
    HL-60 IC50
    0.019 μM
    Compound: Adriamycin
    Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth by CCK-8 assay
    Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth by CCK-8 assay
    		[PMID: 36583957]
    HL-60 IC50
    0.019 μM
    Compound: ADR
    Cytotoxicity against human HL60 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay
    Cytotoxicity against human HL60 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay
    		[PMID: 28068601]
    HL-60 IC50
    0.02 μM
    Compound: Adriamycin
    Cytotoxicity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
    Cytotoxicity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
    		[PMID: 34762434]
    HL-60 IC50
    0.02 μM
    Compound: Adriamycin
    Cytotoxicity against human HL-60 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HL-60 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32880456]
    HL-60 IC50
    0.02 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 31904949]
    HL-60 IC50
    0.02 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 29286660]
    HL-60 IC50
    0.02 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 28418245]
    HL-60 IC50
    0.02 μM
    Compound: Dox
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 26506221]
    HL-60 GI50
    0.02 μM
    Compound: Doxorubicin hydrochloride
    Growth inhibition of human HL60 cells measured after 3 days by trypan blue assay
    Growth inhibition of human HL60 cells measured after 3 days by trypan blue assay
    		[PMID: 29565129]
    HL-60 IC50
    0.04 μM
    Compound: Adriamycin
    Cytotoxicity against Homo sapiens (human) HL60 cells assessed as reduction in cell survival fraction after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HL60 cells assessed as reduction in cell survival fraction after 48 hr by MTT assay
    		10.1007/s00044-011-9703-4
    HL-60 IC50
    0.067 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    		[PMID: 27462726]
    HL-60 IC50
    0.075 μM
    Compound: Adr
    Cytotoxicity in human HL60 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK-8 assay
    Cytotoxicity in human HL60 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK-8 assay
    		[PMID: 31184894]
    HL-60 IC50
    0.076 μM
    Compound: Adr
    Cytotoxicity against human HL60 cells by MTT assay
    Cytotoxicity against human HL60 cells by MTT assay
    		[PMID: 29182349]
    HL-60 IC50
    0.08 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells measured after 72 hrs by CCK8 assay
    Cytotoxicity against human HL60 cells measured after 72 hrs by CCK8 assay
    		[PMID: 31117522]
    HL-60 IC50
    0.08 μM
    Compound: 1
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 20133021]
    HL-60 IC50
    0.1 μM
    Compound: adriamicin
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    		[PMID: 21090801]
    HL-60 IC50
    0.1 μM
    Compound: 1
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    		[PMID: 20133021]
    HL-60 IC50
    0.13 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 21192108]
    HL-60 IC50
    0.14 μM
    Compound: ADM
    Cytotoxicity against human HL60 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    Cytotoxicity against human HL60 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    		[PMID: 30827866]
    HL-60 IC50
    0.18 μM
    Compound: adriamycin
    Cytotoxicity against human HL60 cells by MTT assay
    Cytotoxicity against human HL60 cells by MTT assay
    		[PMID: 19962306]
    HL-60 IC50
    0.2 μM
    Compound: ADM
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 29985604]
    HL-60 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human HL-60 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HL-60 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 32840364]
    HL-60 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HL60 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 27992183]
    HL-60 IC50
    0.22 μM
    Compound: 1
    Cytotoxicity against human HL60 cells after 24 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 24 hrs by MTT assay
    		[PMID: 20133021]
    HL-60 IC50
    0.32 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells after 2 days
    Cytotoxicity against human HL60 cells after 2 days
    		[PMID: 21419530]
    HL-60 IC50
    0.7 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells after 2 days by automatic ELISA reader system
    Cytotoxicity against human HL60 cells after 2 days by automatic ELISA reader system
    		[PMID: 20392646]
    HL-60 IC50
    0.88 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells by MTT assay
    Cytotoxicity against human HL60 cells by MTT assay
    		[PMID: 19836231]
    HL-60 IC50
    0.94 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    		[PMID: 20093033]
    HL60/ADR IC50
    4.3 μM
    Compound: Adriamycin
    Cytotoxicity against Homo sapiens (human) HL60/ADR cells assessed as reduction in cell survival fraction after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HL60/ADR cells assessed as reduction in cell survival fraction after 48 hr by MTT assay
    		10.1007/s00044-011-9703-4
    HL60/ADR IC50
    4.89 μM
    Compound: ADR
    Cytotoxicity against human HL60/ADR cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60/ADR cells after 72 hrs by MTT assay
    		[PMID: 26832219]
    HOP-62 GI50
    0.12 μM
    Compound: ADR
    Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay
    Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay
    		[PMID: 20554354]
    HOP-62 GI50
    0.14 mM
    Compound: Adriamycin
    Growth inhibition of human HOP62 cells after 48 hrs by MTT assay
    Growth inhibition of human HOP62 cells after 48 hrs by MTT assay
    		[PMID: 32631569]
    HOP-62 GI50
    0.14 μM
    Compound: ADR
    Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay
    Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay
    		[PMID: 20444601]
    HOP-62 GI50
    0.14 μM
    Compound: ADR
    Cytotoxicity against human HOP62 cells by sulforhodamine B method
    Cytotoxicity against human HOP62 cells by sulforhodamine B method
    		[PMID: 21459581]
    HT-1080 IC50
    0.008 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33774342]
    HT-1080 IC50
    0.012 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
    Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
    		[PMID: 15387667]
    HT-1080 EC50
    0.02 μM
    Compound: doxorubicin HCl
    Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay
    		[PMID: 12027739]
    HT-1080 ED50
    0.034 μg/mL
    Compound: doxorubicin HCl
    Cytotoxicity against human HT1080 cells after 24 hrs by MTT assay
    Cytotoxicity against human HT1080 cells after 24 hrs by MTT assay
    		[PMID: 9677271]
    HT-1080 IC50
    0.2 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against human HT1080 cells assessed as cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human HT1080 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 11575942]
    HT-1080 IC50
    0.38 μM
    Compound: Adriamycin
    Cytotoxicity against human HT1080 cells assessed as reduction cell viability after 72 hrs by WST8-based colorimetric analysis
    Cytotoxicity against human HT1080 cells assessed as reduction cell viability after 72 hrs by WST8-based colorimetric analysis
    		[PMID: 27332142]
    HT-29 GI50
    0.15 μM
    Compound: doxorubicin hydrochloride
    Antitumor activity against human HT-29 cells after 72 hrs by SRB assay
    Antitumor activity against human HT-29 cells after 72 hrs by SRB assay
    		[PMID: 21718029]
    HT-29 GI50
    0.15 μM
    Compound: DOX HCl
    Growth inhibition against human HT-29 cells after 72 hrs by inverted microscopy
    Growth inhibition against human HT-29 cells after 72 hrs by inverted microscopy
    		[PMID: 23353738]
    HT-29 IC50
    0.559 μM
    Compound: Adr
    Cytotoxicity against human HT-29 cells by SRB assay
    Cytotoxicity against human HT-29 cells by SRB assay
    		[PMID: 29182349]
    HT-29 IC50
    0.58 mg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay
    		[PMID: 22142614]
    HT-29 IC50
    0.95 μM
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    		[PMID: 20093033]
    HT-29 IC50
    1.46 μM
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 27318123]
    HT-29 IC50
    1.76 μM
    Compound: Adriamycin
    Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
    		[PMID: 28222318]
    HT-29 IC50
    1.8 μM
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 33301677]
    HT-29 GI50
    153 nM
    Compound: Doxorubicin HCl
    Growth inhibition of human HT-29 cells after 72 hrs by SRB assay
    Growth inhibition of human HT-29 cells after 72 hrs by SRB assay
    		[PMID: 22607205]
    HT-29 IC50
    2.6 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 34176266]
    HT-29 IC50
    3.8 μM
    Compound: Adriamycin
    Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31268321]
    HT-29 IC50
    3.8 μM
    Compound: Adriamycin
    Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31117521]
    HT-29 IC50
    3.9 μM
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells by MTT assay
    Cytotoxicity against human HT-29 cells by MTT assay
    		[PMID: 19836231]
    HT-29 IC50
    4.2 μM
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells by MTT assay
    Cytotoxicity against human HT-29 cells by MTT assay
    		[PMID: 21875764]
    HT-29 IC50
    4.2 μM
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells by MTT assay
    Cytotoxicity against human HT-29 cells by MTT assay
    		[PMID: 20627721]
    Huh-7 IC50
    14.8 μM
    Compound: Adriamycin
    Cytotoxicity against human HuH7 cells by CCK-8 assay
    Cytotoxicity against human HuH7 cells by CCK-8 assay
    		[PMID: 27704808]
    HUVEC IC50
    4.3 μM
    Compound: ADR
    Cytotoxicity against HUVEC assessed as reduction in cell viability by MTT assay
    Cytotoxicity against HUVEC assessed as reduction in cell viability by MTT assay
    		[PMID: 33097300]
    IMR-32 IC50
    0.02 μM
    Compound: Adriamycin
    Cytotoxicity against Homo sapiens (human) IMR32 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) IMR32 cells by SRB assay
    		10.1007/s00044-010-9500-5
    IMR-32 IC50
    1.7 μM
    Compound: Adriamycin
    Cytotoxicity against human IMR-32 cells assessed as inhibition of cell growth incubated for 30 mins by SRB assay
    Cytotoxicity against human IMR-32 cells assessed as inhibition of cell growth incubated for 30 mins by SRB assay
    		[PMID: 30114660]
    K562 IC50
    0.01 μM
    Compound: Adriamycin
    Antiproliferative activity against human K562 cells after 48 hrs by Alamar blue dye based neubauer hemocytometer method
    Antiproliferative activity against human K562 cells after 48 hrs by Alamar blue dye based neubauer hemocytometer method
    		[PMID: 28045256]
    K562 IC50
    0.01 μM
    Compound: Adriamycine
    Cell growth inhibition of human K562 cells after 48 hrs
    Cell growth inhibition of human K562 cells after 48 hrs
    		[PMID: 20546980]
    K562 IC50
    0.01 μM
    Compound: Adriamycine
    Antiproliferative activity against human K562 cells after 48 hrs
    Antiproliferative activity against human K562 cells after 48 hrs
    		[PMID: 20537765]
    K562 IC50
    0.01 μM
    Compound: adriamycin
    Antiproliferative activity against human K562 cells after 48 hrs
    Antiproliferative activity against human K562 cells after 48 hrs
    		[PMID: 17973361]
    K562 GI50
    0.02 μM
    Compound: Doxorubicin hydrochloride
    Growth inhibition of human K562 cells measured after 3 days by trypan blue assay
    Growth inhibition of human K562 cells measured after 3 days by trypan blue assay
    		[PMID: 29565129]
    K562 IC50
    0.059 μM
    Compound: ADR
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 26832219]
    K562 GI50
    0.17 μM
    Compound: DOX HCl
    Growth inhibition against human K562 cells after 72 hrs by inverted microscopy
    Growth inhibition against human K562 cells after 72 hrs by inverted microscopy
    		[PMID: 23353738]
    K562 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32880456]
    K562 IC50
    0.22 μM
    Compound: Adriamycin
    Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay
    		[PMID: 27503681]
    K562 IC50
    0.3 μM
    Compound: Adriamycin
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 31904949]
    K562 IC50
    0.3 μM
    Compound: ADM
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 29985604]
    K562 IC50
    0.3 μM
    Compound: Adriamycin
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 28418245]
    K562 IC50
    0.3 μM
    Compound: Dox
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 26506221]
    K562 IC50
    0.3 μM
    Compound: adriamycin
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 23806071]
    K562 IC50
    0.3 μM
    Compound: ADM
    Cytotoxicity against human K562 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human K562 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 35993848]
    K562 IC50
    0.3 μM
    Compound: Adriamycin
    Cytotoxicity against human K562 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human K562 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 32840364]
    K562 IC50
    0.36 μM
    Compound: ADM
    Cytotoxicity against human K562 cells after 2 days by MTT assay
    Cytotoxicity against human K562 cells after 2 days by MTT assay
    		[PMID: 21821321]
    K562 IC50
    0.39 μM
    Compound: ADR
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 29335204]
    K562 IC50
    0.43 μM
    Compound: ADR
    Antiproliferative activity against human K562 cells after 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human K562 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 20353152]
    K562 IC50
    0.47 μM
    Compound: Adriamycin
    Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 27318123]
    K562 IC50
    0.51 μM
    Compound: ADM
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 28301155]
    K562 IC50
    0.57 μM
    Compound: Adriamycin
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 28222318]
    K562 IC50
    0.59 μM
    Compound: ADR
    Anti-proliferative activity against human K562 cells measured after 72 hrs by MTS assay
    Anti-proliferative activity against human K562 cells measured after 72 hrs by MTS assay
    		[PMID: 28068095]
    K562 IC50
    0.61 μM
    Compound: ADR
    Antiproliferative activity in human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity in human K562 cells after 48 hrs by MTT assay
    		[PMID: 28570977]
    K562 IC50
    0.63 μM
    Compound: ADM
    Cytotoxicity against human K562 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    		[PMID: 30827866]
    K562 IC50
    0.74 μM
    Compound: ADR
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 33097300]
    K562 IC50
    0.83 μM
    Compound: ADR
    Antiproliferative activity against human K562 cells by MTT assay
    Antiproliferative activity against human K562 cells by MTT assay
    		[PMID: 33132117]
    K562 IC50
    0.92 μM
    Compound: ADM
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 35247755]
    K562 IC50
    0.97 μM
    Compound: ADM
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 29631786]
    K562 IC50
    1.2 μM
    Compound: doxorubicin hydrochloride
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 19256529]
    K562 IC50
    108.4 nM
    Compound: Adriamycin
    Antiproliferative activity against human K562 cells measured after 72 hrs by SRB assay
    Antiproliferative activity against human K562 cells measured after 72 hrs by SRB assay
    		[PMID: 34794817]
    K562 IC50
    2.35 μM
    Compound: Dox
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 22318158]
    K562 IC50
    2.5 μM
    Compound: Adriamycin
    Cytotoxicity against human K562 cells after 4 days by ELISA reader assay
    Cytotoxicity against human K562 cells after 4 days by ELISA reader assay
    		[PMID: 19939682]
    K562 IC50
    4.29 μM
    Compound: ADM
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 28645831]
    K562 IC50
    6.23 μM
    Compound: ADM
    Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 27073052]
    K562 IC50
    77.7 nM
    Compound: ADR
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 28333459]
    K562 IC50
    8.9 μM
    Compound: Adriamycin
    Cytotoxicity against human K562 cells by MTT assay
    Cytotoxicity against human K562 cells by MTT assay
    		[PMID: 25304898]
    K562/A02 IC50
    10.55 μM
    Compound: ADR
    Cytotoxicity against human K562/A02 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562/A02 cells after 72 hrs by MTT assay
    		[PMID: 26832219]
    K562/A02 IC50
    19.21 μM
    Compound: ADM
    Cytotoxicity against human K562/A02 cells after 2 days by MTT assay
    Cytotoxicity against human K562/A02 cells after 2 days by MTT assay
    		[PMID: 21821321]
    K562/A02 IC50
    23.42 μM
    Compound: ADR
    Antiproliferative activity against human K562/A02 cells overexpressing P-gp by MTT assay
    Antiproliferative activity against human K562/A02 cells overexpressing P-gp by MTT assay
    		[PMID: 33132117]
    K562/A02 IC50
    23.81 μM
    Compound: ADR
    Antiproliferative activity against human K562/A02 cells after 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human K562/A02 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 20353152]
    K562/A02 IC50
    24.46 μM
    Compound: ADR
    Anti-proliferative activity against P-gp overexpressing/drug resistant human K562/A02 cells measured after 72 hrs by MTS assay
    Anti-proliferative activity against P-gp overexpressing/drug resistant human K562/A02 cells measured after 72 hrs by MTS assay
    		[PMID: 28068095]
    K562/A02 IC50
    25.04 μM
    Compound: ADR
    Cytotoxicity against human K562/A02 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human K562/A02 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 29335204]
    K562/A02 IC50
    38.02 μM
    Compound: ADM
    Cytotoxicity against human K562/A02 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human K562/A02 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 27073052]
    K562/A02 IC50
    53.95 μM
    Compound: ADM
    Cytotoxicity against human K562/A02 cells overexpressing P-gp after 48 hrs by MTT assay
    Cytotoxicity against human K562/A02 cells overexpressing P-gp after 48 hrs by MTT assay
    		[PMID: 28301155]
    K562/A02 IC50
    54.22 μM
    Compound: ADM
    Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay
    		[PMID: 25464884]
    K562/A02 IC50
    65.57 μM
    Compound: ADM
    Cytotoxicity against human K562/A02 cells overexpressing P-gp assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human K562/A02 cells overexpressing P-gp assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 29631786]
    K562/A02 IC50
    78.34 μM
    Compound: ADM
    Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay
    		[PMID: 35247755]
    K562/A02 IC50
    96.91 μM
    Compound: ADM
    Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay
    		[PMID: 28645831]
    K562/Adr IC50
    18.779 μM
    Compound: Adriamycin
    Antiproliferative activity against human K562/ADR cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human K562/ADR cells after 72 hrs by CCK8 assay
    		[PMID: 27503681]
    K562/Adr IC50
    31191 nM
    Compound: Adriamycin
    Antiproliferative activity against human K562/Adr cells measured after 72 hrs by SRB assay
    Antiproliferative activity against human K562/Adr cells measured after 72 hrs by SRB assay
    		[PMID: 34794817]
    K562/Adr IC50
    3310.2 nM
    Compound: ADR
    Antiproliferative activity against human K562/ADR cells after 72 hrs by MTT assay
    Antiproliferative activity against human K562/ADR cells after 72 hrs by MTT assay
    		[PMID: 28333459]
    KB IC50
    0.01 μM
    Compound: Doxorubicin.HCl
    Cytotoxicity against human KB cells after 48 hrs by MTT assay
    Cytotoxicity against human KB cells after 48 hrs by MTT assay
    		[PMID: 23131338]
    KB GI50
    0.13 μM
    Compound: ADR
    Cytotoxicity against human KB cells after 48 hrs by SRB assay
    Cytotoxicity against human KB cells after 48 hrs by SRB assay
    		[PMID: 20554354]
    KB GI50
    0.13 μM
    Compound: ADR
    Cytotoxicity against human KB cells after 48 hrs by sulforhodamine B based ELISA
    Cytotoxicity against human KB cells after 48 hrs by sulforhodamine B based ELISA
    		[PMID: 21402478]
    KB GI50
    0.16 μM
    Compound: ADR
    Anticancer activity against human KB cells after 48 hrs by SRB assay
    Anticancer activity against human KB cells after 48 hrs by SRB assay
    		[PMID: 20557981]
    KB GI50
    0.17 μM
    Compound: ADR
    Cytotoxicity against human KB cells after 48 hrs by SRB assay
    Cytotoxicity against human KB cells after 48 hrs by SRB assay
    		[PMID: 20444601]
    KB GI50
    0.17 μM
    Compound: ADR
    Cytotoxicity against human KB cells by sulforhodamine B method
    Cytotoxicity against human KB cells by sulforhodamine B method
    		[PMID: 21459581]
    KB GI50
    0.19 μM
    Compound: ADR
    Cytotoxicity against human KB cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human KB cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21194809]
    KB IC50
    0.27 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human KB cells after 45 hrs by resazurin microplate assay
    Cytotoxicity against human KB cells after 45 hrs by resazurin microplate assay
    		[PMID: 21473608]
    KB IC50
    0.28 μM
    Compound: doxorubicin hydrochloride
    Cytotoxicity against human KB cells after 45 hrs by resazurin microplate assay
    Cytotoxicity against human KB cells after 45 hrs by resazurin microplate assay
    		[PMID: 20364867]
    KB IC50
    0.57 μM
    Compound: Adr
    Cytotoxicity against human KB cells by SRB assay
    Cytotoxicity against human KB cells by SRB assay
    		[PMID: 29182349]
    KB IC50
    0.6 μM
    Compound: Adriamycin
    Cytotoxicity against human KB cells by MTT assay
    Cytotoxicity against human KB cells by MTT assay
    		[PMID: 21875764]
    KB IC50
    0.6 μM
    Compound: Adriamycin
    Cytotoxicity against human KB cells by MTT assay
    Cytotoxicity against human KB cells by MTT assay
    		[PMID: 20627721]
    KB IC50
    0.84 μM
    Compound: DOX
    Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 24686017]
    KB IC50
    0.84 μM
    Compound: DOX
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    		[PMID: 22574992]
    KB IC50
    1.2 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human KB cells by resazurin microplate assay
    Cytotoxicity against human KB cells by resazurin microplate assay
    		[PMID: 21995505]
    KB IC50
    1.66 μg/mL
    Compound: ADR
    Cytotoxicity against human KB cells after 48 hrs by MTT assay
    Cytotoxicity against human KB cells after 48 hrs by MTT assay
    		[PMID: 20724170]
    KB IC50
    10 μg/mL
    Compound: adriamycin
    Cytotoxicity against human KB cells by MTT assay
    Cytotoxicity against human KB cells by MTT assay
    		[PMID: 17512094]
    KB IC50
    2.2 μM
    Compound: Adriamycin
    Cytotoxicity against human KB cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human KB cells incubated for 48 hrs by MTT assay
    		[PMID: 32394716]
    KB IC50
    3.2 μM
    Compound: Adriamycin
    Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31268321]
    KB-V1 IC50
    1.02 μM
    Compound: 1
    Cytotoxicity against human vinblastine-resistant KBV1 cells after 72 hrs by MTT assay in presence of 24 mM ABC transporter inhibitor verapamil hydrochloride
    Cytotoxicity against human vinblastine-resistant KBV1 cells after 72 hrs by MTT assay in presence of 24 mM ABC transporter inhibitor verapamil hydrochloride
    		[PMID: 20133021]
    KB-V1 IC50
    18.3 μM
    Compound: 1
    Cytotoxicity against human vinblastine-resistant KBV1 cells after 72 hrs by MTT assay
    Cytotoxicity against human vinblastine-resistant KBV1 cells after 72 hrs by MTT assay
    		[PMID: 20133021]
    KB-V1 IC50
    35.6 μM
    Compound: 1
    Cytotoxicity against human vinblastine-resistant KBV1 cells after 48 hrs by MTT assay
    Cytotoxicity against human vinblastine-resistant KBV1 cells after 48 hrs by MTT assay
    		[PMID: 20133021]
    KB-V1 IC50
    59.9 μM
    Compound: 1
    Cytotoxicity against human vinblastine-resistant KBV1 cells after 24 hrs by MTT assay
    Cytotoxicity against human vinblastine-resistant KBV1 cells after 24 hrs by MTT assay
    		[PMID: 20133021]
    KG-1a IC50
    0.08 μM
    Compound: ADR
    Cytotoxicity against human KG1a cells assessed as decrease in cell proliferation after 48 hrs by MTT assay
    Cytotoxicity against human KG1a cells assessed as decrease in cell proliferation after 48 hrs by MTT assay
    		[PMID: 28068601]
    KG-1a IC50
    0.82 μM
    Compound: ADR
    Cytotoxicity against human KG1a cells after 72 hrs by MTT assay
    Cytotoxicity against human KG1a cells after 72 hrs by MTT assay
    		[PMID: 26832219]
    L02 IC50
    0.2 μM
    Compound: ADM
    Cytotoxicity against human L02 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human L02 cells assessed as reduction in cell viability by SRB assay
    		[PMID: 35993848]
    L02 IC50
    0.5 μM
    Compound: Adriamycin
    Cytotoxicity against human L02 cells after 24 hrs by SRB method
    Cytotoxicity against human L02 cells after 24 hrs by SRB method
    		[PMID: 31904949]
    L02 IC50
    0.7 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human L02 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human L02 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 34176266]
    L02 IC50
    0.79 μM
    Compound: ADR
    Cytotoxicity against human L02 cells measured after 48 hrs by MTT assay
    Cytotoxicity against human L02 cells measured after 48 hrs by MTT assay
    		[PMID: 30837097]
    L02 IC50
    13.5 μM
    Compound: Adriamycin
    Cytotoxicity against human LO2 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human LO2 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31013087]
    L1210 ED50
    0.07 μg/mL
    Compound: Adriamycin
    Anticancer activity against mouse L1210 cells assessed as reduction in cell viability for 72 hrs by MTT assay
    Anticancer activity against mouse L1210 cells assessed as reduction in cell viability for 72 hrs by MTT assay
    		[PMID: 35367708]
    L929 IC50
    7.5 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against mouse L929 cells after 72 hrs by MTT assay
    Antiproliferative activity against mouse L929 cells after 72 hrs by MTT assay
    		[PMID: 29884536]
    Lewis lung carcinoma cell line IC50
    0.23 μM
    Compound: adriamycine
    Cytotoxicity activity against mouse LLC cells after 48 hrs by MTT assay
    Cytotoxicity activity against mouse LLC cells after 48 hrs by MTT assay
    		[PMID: 19618898]
    LoVo IC50
    0.11 μM
    Compound: DOX
    Cytotoxicity against human LoVo cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against human LoVo cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 24686017]
    LoVo IC50
    0.11 μM
    Compound: DOX
    Cytotoxicity against human LoVo cells after 72 hrs by SRB assay
    Cytotoxicity against human LoVo cells after 72 hrs by SRB assay
    		[PMID: 22574992]
    LoVo IC50
    0.2 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
    Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
    		[PMID: 15387667]
    LoVo GI50
    0.24 μM
    Compound: DOX HCl
    Growth inhibition against human LoVo cells after 72 hrs by inverted microscopy
    Growth inhibition against human LoVo cells after 72 hrs by inverted microscopy
    		[PMID: 23353738]
    LoVo IC50
    13.2 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human doxorubicin-resistant LoVo cells after 72 hrs by MTT assay
    Cytotoxicity against human doxorubicin-resistant LoVo cells after 72 hrs by MTT assay
    		[PMID: 15387667]
    MCF-10A GI50
    0.04 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MCF10A cells assessed as cell growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human MCF10A cells assessed as cell growth inhibition after 48 hrs by SRB assay
    		[PMID: 27598688]
    MCF-10A IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay
    		[PMID: 29286660]
    MCF-10A IC50
    0.86 μM
    Compound: ADR
    Antiproliferative activity against human MCF-10A cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human MCF-10A cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 34992039]
    MCF-10A IC50
    0.89 μM
    Compound: ADR
    Cytotoxic activity against human MCF-10A assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxic activity against human MCF-10A assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35390712]
    MCF-10A IC50
    0.93 μM
    Compound: ADM
    Cytotoxicity against human MCF10A cells after 72 hrs by cell counting kit-8 analysis
    Cytotoxicity against human MCF10A cells after 72 hrs by cell counting kit-8 analysis
    		[PMID: 29174815]
    MCF-10A IC50
    1.11 μM
    Compound: Doxorubicin
    Growth inhibition of human MCF10A cells after 72 hrs by CellTiter-Blue assay
    Growth inhibition of human MCF10A cells after 72 hrs by CellTiter-Blue assay
    		[PMID: 24153206]
    MCF7 IC50
    < 0.068 mg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 22142614]
    MCF7 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay
    Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay
    		10.1007/s00044-012-0423-1
    MCF7 GI50
    < 0.1 μM
    Compound: ADR
    Growth inhibition of Homo sapiens (human) MCF-7 cells after 48 hr by SRB assay
    Growth inhibition of Homo sapiens (human) MCF-7 cells after 48 hr by SRB assay
    		10.1007/s00044-011-9688-z
    MCF7 GI50
    < 0.1 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 28258796]
    MCF7 GI50
    < 0.1 μM
    Compound: ADR
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    		[PMID: 26994845]
    MCF7 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 20554354]
    MCF7 IC50
    < 0.1 μM
    Compound: Adiramycin
    Cytotoxicity against human MCF7 cells by SRB method
    Cytotoxicity against human MCF7 cells by SRB method
    		[PMID: 24951333]
    MCF7 IC50
    < 1 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    		[PMID: 28757067]
    MCF7 IC50
    < 1 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 31804070]
    MCF7 IC50
    < 10 μM
    Compound: Adriamycin
    Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35694689]
    MCF7 IC50
    > 10 μM
    Compound: adriamicin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 21090801]
    MCF7 GI50
    0.00018 μM
    Compound: Adriamycin
    Growth inhibition of human MCF7 cells after 48 hrs by SRB assay
    Growth inhibition of human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 31330449]
    MCF7 IC50
    0.0012 μM
    Compound: Adiramycin
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth by MTT assay
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 33940466]
    MCF7 GI50
    0.054 μM
    Compound: Adr
    Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay
    		[PMID: 29102180]
    MCF7 GI50
    0.054 μM
    Compound: Adr
    Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay
    		[PMID: 26741854]
    MCF7 IC50
    0.075 μM
    Compound: Doxorubicin
    Growth inhibition of human MCF7 cells after 72 hrs by CellTiter-Blue assay
    Growth inhibition of human MCF7 cells after 72 hrs by CellTiter-Blue assay
    		[PMID: 24153206]
    MCF7 IC50
    0.08 μM
    Compound: 1
    Cytotoxicity against human topotecan-resistant MCF7 cells after 72 hrs by MTT assay in presence of 1.2 mM BCRP inhibitor fumitremorgin C
    Cytotoxicity against human topotecan-resistant MCF7 cells after 72 hrs by MTT assay in presence of 1.2 mM BCRP inhibitor fumitremorgin C
    		[PMID: 20133021]
    MCF7 IC50
    0.1 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 29286660]
    MCF7 GI50
    0.13 μM
    Compound: ADR
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B based ELISA
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B based ELISA
    		[PMID: 21402478]
    MCF7 IC50
    0.15 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay
    		[PMID: 21192108]
    MCF7 GI50
    0.17 mM
    Compound: Adriamycin
    Growth inhibition of human MCF7 cells after 48 hrs by MTT assay
    Growth inhibition of human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 32631569]
    MCF7 GI50
    0.17 μM
    Compound: ADR
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 20444601]
    MCF7 GI50
    0.17 μM
    Compound: ADR
    Cytotoxicity against human MCF7 cells by sulforhodamine B method
    Cytotoxicity against human MCF7 cells by sulforhodamine B method
    		[PMID: 21459581]
    MCF7 IC50
    0.2 μM
    Compound: ADM
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 28749671]
    MCF7 GI50
    0.23 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as growth inhibition by SRB assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition by SRB assay
    		[PMID: 24507920]
    MCF7 IC50
    0.39 μM
    Compound: ADR
    Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 20353152]
    MCF7 IC50
    0.4 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 30049584]
    MCF7 IC50
    0.42 μM
    Compound: ADR
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 30677614]
    MCF7 IC50
    0.44 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 24686017]
    MCF7 IC50
    0.44 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
    		[PMID: 22574992]
    MCF7 IC50
    0.65 μM
    Compound: adriamycine
    Cytotoxic activity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxic activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 19618898]
    MCF7 IC50
    0.67 μM
    Compound: ADR
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 35339100]
    MCF7 IC50
    0.67 μM
    Compound: ADR
    Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay
    		[PMID: 30837097]
    MCF7 EC50
    0.7 μM
    Compound: Adriamycin
    Antiproliferative activity against human ER-positive MCF7 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human ER-positive MCF7 cells measured after 48 hrs by MTT assay
    		[PMID: 27344488]
    MCF7 IC50
    0.7 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 29215886]
    MCF7 IC50
    0.72 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 33689875]
    MCF7 IC50
    0.8 μM
    Compound: Adriamycin
    Cytotoxicity against Homo sapiens (human) MCF7 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) MCF7 cells by SRB assay
    		10.1007/s00044-010-9500-5
    MCF7 IC50
    0.88 μM
    Compound: AMD
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 25408835]
    MCF7 IC50
    0.99 μM
    Compound: Adriamycin
    Cytotoxicity against human wild-type MCF7 cells after 72 hrs
    Cytotoxicity against human wild-type MCF7 cells after 72 hrs
    		[PMID: 28720329]
    MCF7 IC50
    1 μM
    Compound: Adriamycin
    Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31268321]
    MCF7 IC50
    1 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    		[PMID: 27240278]
    MCF7 IC50
    1 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 30222343]
    MCF7 IC50
    1 μM
    Compound: 1
    Cytotoxicity against human topotecan-resistant MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human topotecan-resistant MCF7 cells after 72 hrs by MTT assay
    		[PMID: 20133021]
    MCF7 IC50
    1.02 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 34081476]
    MCF7 IC50
    1.1 μM
    Compound: ADR
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 33097300]
    MCF7 IC50
    1.13 μM
    Compound: ADR
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35390712]
    MCF7 IC50
    1.2 μM
    Compound: 4; ADR
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 28803046]
    MCF7 IC50
    1.2 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 34176266]
    MCF7 IC50
    1.3 μM
    Compound: 1
    Cytotoxicity against human topotecan-resistant MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human topotecan-resistant MCF7 cells after 48 hrs by MTT assay
    		[PMID: 20133021]
    MCF7 IC50
    1.3 μM
    Compound: Adriamycin
    Cytotoxicity against vinblastine-sensitive human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against vinblastine-sensitive human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 28006904]
    MCF7 IC50
    1.31 μM
    Compound: ADR
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 34992039]
    MCF7 IC50
    1.5 μM
    Compound: doxorubicin hydrochloride
    Cytotoxicity against human MCF7 cells after 45 hrs by resazurin microplate assay
    Cytotoxicity against human MCF7 cells after 45 hrs by resazurin microplate assay
    		[PMID: 20364867]
    MCF7 IC50
    1.65 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 21123066]
    MCF7 IC50
    1.72 μM
    Compound: Adriamycin
    Growth inhibition of human MCF7 cells after 48 hrs by MTT assay
    Growth inhibition of human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 29903663]
    MCF7 IC50
    15 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human MCF7 cells by resazurin microplate assay
    Cytotoxicity against human MCF7 cells by resazurin microplate assay
    		[PMID: 21995505]
    MCF7 IC50
    15.8 μM
    Compound: Adriamycin
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
    		[PMID: 34648295]
    MCF7 IC50
    18.9 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 4 days by MTT assay
    Cytotoxicity against human MCF7 cells after 4 days by MTT assay
    		[PMID: 20619511]
    MCF7 IC50
    2.1 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 4 days by ELISA reader assay
    Cytotoxicity against human MCF7 cells after 4 days by ELISA reader assay
    		[PMID: 19939682]
    MCF7 IC50
    2.3 μM
    Compound: ADR
    Antiproliferative activity in human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity in human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 28570977]
    MCF7 IC50
    2.5 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay
    		[PMID: 32394716]
    MCF7 IC50
    2.78 μM
    Compound: Doxorubicin.HCl
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 25529734]
    MCF7 IC50
    22.2 nM
    Compound: Adriamycin
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 27213819]
    MCF7 IC50
    25.6 nM
    Compound: Adriamycin
    Cytotoxicity in human MCF7 assessed as inhibition in cell growth measured after 24 hrs by MTT assay
    Cytotoxicity in human MCF7 assessed as inhibition in cell growth measured after 24 hrs by MTT assay
    		[PMID: 35084853]
    MCF7 IC50
    25.9 μM
    Compound: Adriamycin
    Antiproliferative activity against human MCF7 cells by SRB assay
    Antiproliferative activity against human MCF7 cells by SRB assay
    		[PMID: 32688198]
    MCF7 IC50
    27.92 μM
    Compound: ADR
    Antiproliferative activity against human MCF7/ADR cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7/ADR cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 34992039]
    MCF7 IC50
    28.4 μM
    Compound: ADR
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 34649064]
    MCF7 IC50
    3.2 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF-7 cells assessed as cell viability inhibition for 48 hrs by MTT assay
    Cytotoxicity against human MCF-7 cells assessed as cell viability inhibition for 48 hrs by MTT assay
    		[PMID: 33913326]
    MCF7 IC50
    3.23 ng/mL
    Compound: 2b
    Concentration required to inhibit proliferation of human mammary adenocarcinoma MCF-7 cell line was determined using MTT assay
    Concentration required to inhibit proliferation of human mammary adenocarcinoma MCF-7 cell line was determined using MTT assay
    		[PMID: 15324908]
    MCF7 IC50
    4.6 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 29884536]
    MCF7 IC50
    4.9 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human MCF7 cells after 45 hrs by resazurin microplate assay
    Cytotoxicity against human MCF7 cells after 45 hrs by resazurin microplate assay
    		[PMID: 21473608]
    MCF7 IC50
    44.8 nM
    Compound: Adriamycin
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 28763646]
    MCF7 IC50
    44.82 nM
    Compound: Adriamycin
    Antiproliferative activity against human MCF7 cells after 48 to 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 to 72 hrs by MTT assay
    		[PMID: 29754076]
    MCF7 IC50
    5.1 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 21875764]
    MCF7 IC50
    5.1 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 20627721]
    MCF7 IC50
    5.3 μM
    Compound: Adriamycin
    Cytotoxicity against multidrug resistant human MCF7 cells cultured in vinblastine containing medium assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against multidrug resistant human MCF7 cells cultured in vinblastine containing medium assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 28006904]
    MCF7 IC50
    5.31 μM
    Compound: Adriamycin
    Antiproliferative activity against human MCF7 cells measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human MCF7 cells measured after 72 hrs by CCK8 assay
    		[PMID: 27654394]
    MCF7 IC50
    5.75 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 3 days
    Cytotoxicity against human MCF7 cells after 3 days
    		[PMID: 19954977]
    MCF7 GI50
    50.2 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    MCF7 IC50
    6.2 μM
    Compound: 1
    Cytotoxicity against human topotecan-resistant MCF7 cells after 24 hrs by MTT assay
    Cytotoxicity against human topotecan-resistant MCF7 cells after 24 hrs by MTT assay
    		[PMID: 20133021]
    MCF7 IC50
    9.2 μM
    Compound: Adriamycin
    Cytotoxicity against multidrug resistant human MCF7 cells cultured in vinblastine free medium assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against multidrug resistant human MCF7 cells cultured in vinblastine free medium assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 28006904]
    MCF7 IC50
    94.1 μM
    Compound: AMD
    Cytotoxicity against adriamycin-resistant human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against adriamycin-resistant human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 25408835]
    MDA-MB-231 IC50
    < 0.068 mg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
    		[PMID: 22142614]
    MDA-MB-231 GI50
    0.07 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay
    		[PMID: 29878761]
    MDA-MB-231 GI50
    0.08 μM
    Compound: Adriamycin
    Growth inhibition of human MDA-MB-231 cells by SRB assay
    Growth inhibition of human MDA-MB-231 cells by SRB assay
    		[PMID: 36040099]
    MDA-MB-231 GI50
    0.09 μM
    Compound: doxorubicin hydrochloride
    Antitumor activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    Antitumor activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    		[PMID: 21718029]
    MDA-MB-231 GI50
    0.12 μM
    Compound: Adr
    Antiproliferative activity against human MDA-MB-231 cells after 96 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 96 hrs by MTT assay
    		[PMID: 29102180]
    MDA-MB-231 IC50
    0.15 μM
    Compound: ADR
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method
    		[PMID: 35302779]
    MDA-MB-231 GI50
    0.15 μM
    Compound: ADR
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 31668073]
    MDA-MB-231 IC50
    0.19 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33774342]
    MDA-MB-231 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 34282909]
    MDA-MB-231 IC50
    0.2 μM
    Compound: ADM
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    		[PMID: 35380848]
    MDA-MB-231 IC50
    0.3 μM
    Compound: Adriamycin
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    		[PMID: 31397570]
    MDA-MB-231 IC50
    0.3 μM
    Compound: ADM
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability by SRB assay
    		[PMID: 35993848]
    MDA-MB-231 IC50
    0.37 μM
    Compound: Adriamycin
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
    		[PMID: 35121401]
    MDA-MB-231 IC50
    0.39 μM
    Compound: Doxorubicin
    Growth inhibition of human MDA-MB-231 cells after 72 hrs by CellTiter-Blue assay
    Growth inhibition of human MDA-MB-231 cells after 72 hrs by CellTiter-Blue assay
    		[PMID: 24153206]
    MDA-MB-231 IC50
    0.4 μM
    Compound: ADR
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 35762988]
    MDA-MB-231 IC50
    0.4 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells after 2 days by automatic ELISA reader system
    Cytotoxicity against human MDA-MB-231 cells after 2 days by automatic ELISA reader system
    		[PMID: 20392646]
    MDA-MB-231 IC50
    0.54 μM
    Compound: Doxorubicin.HCl
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 30223117]
    MDA-MB-231 IC50
    0.6 μM
    Compound: Adriamycin
    Anti-proliferative activity against human MDA-MB-231 cells by XTT assay
    Anti-proliferative activity against human MDA-MB-231 cells by XTT assay
    		[PMID: 25442319]
    MDA-MB-231 IC50
    0.8 μM
    Compound: ADR
    Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by MTT assay
    		[PMID: 30739826]
    MDA-MB-231 IC50
    0.82 μM
    Compound: ADR
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 34992039]
    MDA-MB-231 IC50
    0.84 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells after 2 days
    Cytotoxicity against human MDA-MB-231 cells after 2 days
    		[PMID: 21419530]
    MDA-MB-231 IC50
    0.86 μM
    Compound: ADR
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35390712]
    MDA-MB-231 IC50
    1.16 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells after 3 days
    Cytotoxicity against human MDA-MB-231 cells after 3 days
    		[PMID: 19954977]
    MDA-MB-231 IC50
    1.2 μM
    Compound: DOX.HCl
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 28445049]
    MDA-MB-231 IC50
    1.45 μM
    Compound: Dox
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 22318158]
    MDA-MB-231 IC50
    1.67 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    		[PMID: 19836231]
    MDA-MB-231 IC50
    1.8 μM
    Compound: 4; ADR
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 28803046]
    MDA-MB-231 IC50
    2.19 μM
    Compound: Adriamycin
    Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay
    Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 29903663]
    MDA-MB-231 IC50
    2.26 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 21144747]
    MDA-MB-231 EC50
    2.3 μM
    Compound: Adriamycin
    Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay
    		[PMID: 27344488]
    MDA-MB-231 IC50
    2.94 μM
    Compound: ADR
    Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay
    		[PMID: 30837097]
    MDA-MB-231 IC50
    3 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 29286660]
    MDA-MB-231 IC50
    3.15 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 20093033]
    MDA-MB-231 IC50
    3.6 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay
    		[PMID: 27707625]
    MDA-MB-231 IC50
    4.06 μM
    Compound: Doxorubicin.HCl
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 25529734]
    MDA-MB-231 IC50
    4.4 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells after 4 days by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 4 days by MTT assay
    		[PMID: 20619511]
    MDA-MB-231 IC50
    5.18 μM
    Compound: Adriamycin
    Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by Ez-cytox assay
    Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by Ez-cytox assay
    		[PMID: 31398033]
    MDA-MB-435 GI50
    < 0.1 μM
    Compound: ADR
    Anticancer activity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    Anticancer activity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    		[PMID: 26994845]
    MDA-MB-435 GI50
    < 0.1 μM
    Compound: Adriamycin
    Anticancer activity against human MDA-MB-435 cells assessed as cell growth inhibition by sulforhodamine B assay
    Anticancer activity against human MDA-MB-435 cells assessed as cell growth inhibition by sulforhodamine B assay
    		[PMID: 35694689]
    MDA-MB-435 IC50
    0.77 μg/mL
    Compound: Dox
    Cytotoxicity against Homo sapiens (human) MDA-MB-435 cells assessed as inhibition of cell viability by MTT assay
    Cytotoxicity against Homo sapiens (human) MDA-MB-435 cells assessed as inhibition of cell viability by MTT assay
    		10.1007/s00044-013-0486-7
    MDA-MB-435 IC50
    0.93 μg/mL
    Compound: Dox
    Cytotoxicity against Homo sapiens (human) MDA-MB-435 cells assessed as inhibition of cell viability by SRB assay
    Cytotoxicity against Homo sapiens (human) MDA-MB-435 cells assessed as inhibition of cell viability by SRB assay
    		10.1007/s00044-013-0486-7
    MDA-MB-436 IC50
    2.03 μM
    Compound: Adriamycin
    Antiproliferative activity against human MDA-MB-436 cells measured after 72 hrs by Ez-cytox assay
    Antiproliferative activity against human MDA-MB-436 cells measured after 72 hrs by Ez-cytox assay
    		[PMID: 31398033]
    MDA-MB-468 EC50
    0.7 μM
    Compound: Adriamycin
    Antiproliferative activity against human ER-triple negative MDA-MB-468 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human ER-triple negative MDA-MB-468 cells measured after 48 hrs by MTT assay
    		[PMID: 27344488]
    MDA-MB-468 GI50
    10.5 μM
    Compound: ADR
    Anticancer activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    Anticancer activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    		[PMID: 26994845]
    MDA-MB-468 IC50
    2.15 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay
    Cytotoxicity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay
    		[PMID: 27707625]
    MG-63 IC50
    2.2 μM
    Compound: Adriamycin
    Cytotoxicity against human MG63 cells by MTT assay
    Cytotoxicity against human MG63 cells by MTT assay
    		[PMID: 27704808]
    MG-63 IC50
    3.4 μM
    Compound: Adriamycin
    Cytotoxicity against human MG63 cells by MTT assay
    Cytotoxicity against human MG63 cells by MTT assay
    		[PMID: 23477504]
    MG-63 IC50
    5.2 μM
    Compound: Adriamycin
    Growth inhibition of human MG63 cells by MTT method
    Growth inhibition of human MG63 cells by MTT method
    		[PMID: 25611131]
    MGC-803 IC50
    0.2 μM
    Compound: ADM
    Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
    Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
    		[PMID: 29985604]
    MGC-803 IC50
    0.2 μM
    Compound: Dox
    Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
    Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
    		[PMID: 26506221]
    MGC-803 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human MGC803 cells after 24 hrs by SRB method
    Cytotoxicity against human MGC803 cells after 24 hrs by SRB method
    		[PMID: 31904949]
    MGC-803 IC50
    0.48 μM
    Compound: Adriamycin
    Anticancer activity against human MGC-803 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    Anticancer activity against human MGC-803 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    		[PMID: 35367708]
    MGC-803 IC50
    0.71 μM
    Compound: ADM
    Growth inhibition of human MGC803 cells after 72 hrs by MTT assay
    Growth inhibition of human MGC803 cells after 72 hrs by MTT assay
    		[PMID: 25064351]
    MGC-803 IC50
    2.53 μM
    Compound: Adriamycin
    Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay
    Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay
    		[PMID: 21144747]
    MGC-803 IC50
    2.56 μM
    Compound: Dox
    Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay
    Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay
    		[PMID: 22318158]
    MIA PaCa-2 IC50
    0.25 μM
    Compound: Adriamycin
    Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth by CCK-8 assay
    Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth by CCK-8 assay
    		[PMID: 36583957]
    MOLT-4 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against Homo sapiens (human) MOLT4 cells after 48 hr by SRB assay
    Cytotoxicity against Homo sapiens (human) MOLT4 cells after 48 hr by SRB assay
    		10.1007/s00044-012-0423-1
    MOLT-4 IC50
    0.07 μM
    Compound: Dox
    Cytotoxicity against human MOLT4 cells after 48 hrs by Alamar blue assay
    Cytotoxicity against human MOLT4 cells after 48 hrs by Alamar blue assay
    		[PMID: 25064348]
    MV4-11 IC50
    0.006 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against Homo sapiens (human) MV411 cells after 72 hr by MTT assay
    Antiproliferative activity against Homo sapiens (human) MV411 cells after 72 hr by MTT assay
    		10.1007/s00044-012-0443-x
    MV4-11 IC50
    0.006 μM
    Compound: Doxorubicin HCl
    Cytotoxicity against human MV4-11 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MV4-11 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 24686018]
    MV4-11 IC50
    0.006 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay
    		[PMID: 22748378]
    MV4-11 IC50
    0.14 μM
    Compound: Adriamycin
    Cytotoxicity against human MV4-11 cells assessed as inhibition of cell growth measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human MV4-11 cells assessed as inhibition of cell growth measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 33356258]
    NB-4 IC50
    0.4 μM
    Compound: Adriamycin
    Cytotoxicity against human NB4 cells after 72 hrs by MTT assay
    Cytotoxicity against human NB4 cells after 72 hrs by MTT assay
    		[PMID: 28418245]
    NCI/ADR-RES EC50
    > 10 μM
    Compound: Adriamycin
    Antiproliferative activity against human MCF7/ADR cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7/ADR cells measured after 48 hrs by MTT assay
    		[PMID: 27344488]
    NCI/ADR-RES IC50
    > 50 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7/ADR cells after 72 hrs
    Cytotoxicity against human MCF7/ADR cells after 72 hrs
    		[PMID: 28720329]
    NCI/ADR-RES GI50
    0.52 μM
    Compound: Adr
    Antiproliferative activity against human MCF7/ADR cells after 96 hrs by MTT assay
    Antiproliferative activity against human MCF7/ADR cells after 96 hrs by MTT assay
    		[PMID: 26741854]
    NCI/ADR-RES GI50
    0.54 μM
    Compound: Adr
    Antiproliferative activity against human MCF7/ADR cells after 96 hrs by MTT assay
    Antiproliferative activity against human MCF7/ADR cells after 96 hrs by MTT assay
    		[PMID: 29102180]
    NCI/ADR-RES IC50
    2.9 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7/ADR cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7/ADR cells after 72 hrs by MTT assay
    		[PMID: 29286660]
    NCI/ADR-RES IC50
    232.5 μM
    Compound: ADR
    Antiproliferative activity against adriamycin resistant human MCF7/ADR cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against adriamycin resistant human MCF7/ADR cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 34649064]
    NCI/ADR-RES IC50
    24.92 μM
    Compound: ADR
    Antiproliferative activity against human NCI-ADR-RES cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human NCI-ADR-RES cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35390712]
    NCI/ADR-RES IC50
    39.52 μM
    Compound: ADR
    Cytotoxicity against human MCF7/ADR cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7/ADR cells after 72 hrs by MTT assay
    		[PMID: 30677614]
    NCI/ADR-RES IC50
    44.9 μM
    Compound: ADR
    Antiproliferative activity against human MCF7/ADR cells after 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human MCF7/ADR cells after 72 hrs by sulforhodamine B assay
    		[PMID: 20353152]
    NCI/ADR-RES IC50
    50.74 μM
    Compound: Adriamycin
    Growth inhibition of human MCF7/ADR cells after 48 hrs by MTT assay
    Growth inhibition of human MCF7/ADR cells after 48 hrs by MTT assay
    		[PMID: 29903663]
    NCI/ADR-RES IC50
    5300 nM
    Compound: adriamycin
    Antiproliferative activity against adriamycin resistant human MCF7/ADR cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    Antiproliferative activity against adriamycin resistant human MCF7/ADR cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    		[PMID: 25208345]
    NCI/ADR-RES IC50
    54749.19 nM
    Compound: Adriamycin
    Antiproliferative activity against human MCF7/ADR cells after 48 to 72 hrs by MTT assay
    Antiproliferative activity against human MCF7/ADR cells after 48 to 72 hrs by MTT assay
    		[PMID: 29754076]
    NCI/ADR-RES IC50
    54750 nM
    Compound: Adriamycin
    Antiproliferative activity against human MCF7/ADR cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7/ADR cells after 48 hrs by MTT assay
    		[PMID: 28763646]
    NCI/ADR-RES IC50
    58.8 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7/ADR cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    Cytotoxicity against human MCF7/ADR cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    		[PMID: 27240278]
    NCI/ADR-RES IC50
    8153 nM
    Compound: Adriamycin
    Cytotoxicity against P-gp overexpressing human MCF7/ADR cells assessed as reduction in cell growth after 24 hrs by MTT assay
    Cytotoxicity against P-gp overexpressing human MCF7/ADR cells assessed as reduction in cell growth after 24 hrs by MTT assay
    		[PMID: 27213819]
    NCI/ADR-RES IC50
    8216 nM
    Compound: Adriamycin
    Cytotoxicity in human NCI-ADR-RES assessed as inhibition in cell growth measured after 24 hrs by MTT assay
    Cytotoxicity in human NCI-ADR-RES assessed as inhibition in cell growth measured after 24 hrs by MTT assay
    		[PMID: 35084853]
    NCI/ADR-RES IC50
    85.14 μM
    Compound: ADR
    Antiproliferative activity against human MCF7/ADR cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7/ADR cells after 48 hrs by MTT assay
    		[PMID: 35339100]
    NCI-H1299 IC50
    0.8 μM
    Compound: Adriamycin
    Cytotoxicity in human NCI-H1299 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human NCI-H1299 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31268321]
    NCI-H1299 IC50
    4.7 μM
    Compound: Adriamycin
    Cytotoxicity against human NCI-H12199 cells assessed as cell viability inhibition for 48 hrs by MTT assay
    Cytotoxicity against human NCI-H12199 cells assessed as cell viability inhibition for 48 hrs by MTT assay
    		[PMID: 33913326]
    NCI-H187 IC50
    0.086 μM
    Compound: doxorubicin hydrochloride
    Cytotoxicity against human NCI-H187 cells after 45 hrs by resazurin microplate assay
    Cytotoxicity against human NCI-H187 cells after 45 hrs by resazurin microplate assay
    		[PMID: 20364867]
    NCI-H187 IC50
    0.23 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human NCI-H187 cells after 45 hrs by resazurin microplate assay
    Cytotoxicity against human NCI-H187 cells after 45 hrs by resazurin microplate assay
    		[PMID: 21473608]
    NCI-H187 IC50
    0.25 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human NCI-H187 cells by resazurin microplate assay
    Cytotoxicity against human NCI-H187 cells by resazurin microplate assay
    		[PMID: 21995505]
    NCI-H1975 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human NCI-H1975 cells after 24 hrs by sulforhodamine B assay
    Cytotoxicity against human NCI-H1975 cells after 24 hrs by sulforhodamine B assay
    		[PMID: 28418245]
    NCI-H1975 IC50
    0.8 μM
    Compound: Dox
    Cytotoxicity against human NCI-H1975 cells after 72 hrs by MTT assay
    Cytotoxicity against human NCI-H1975 cells after 72 hrs by MTT assay
    		[PMID: 26506221]
    NCI-H226 GI50
    < 0.1 μM
    Compound: ADR
    Anticancer activity against human NCI-H226 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    Anticancer activity against human NCI-H226 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    		[PMID: 26994845]
    NCI-H226 IC50
    0.3 μM
    Compound: Adriamycin
    Antiproliferative activity against human NCI-H226 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    Antiproliferative activity against human NCI-H226 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    		[PMID: 31397570]
    NCI-H23 GI50
    0.08 μM
    Compound: Adriamycin
    Growth inhibition of human NCI-H23 cells by SRB assay
    Growth inhibition of human NCI-H23 cells by SRB assay
    		[PMID: 36040099]
    NCI-H23 GI50
    0.08 μM
    Compound: Adriamycin
    Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay
    		[PMID: 29878761]
    NCI-H23 IC50
    0.09 μM
    Compound: ADR
    Cytotoxicity against human NCI-H23 cells by colorimetric method
    Cytotoxicity against human NCI-H23 cells by colorimetric method
    		[PMID: 32916298]
    NCI-H23 GI50
    0.14 μM
    Compound: ADR
    Cytotoxicity against human NCI-H23 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Cytotoxicity against human NCI-H23 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 31668073]
    NCI-H23 IC50
    0.16 μM
    Compound: ADR
    Cytotoxicity against human NCI-H23 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method
    Cytotoxicity against human NCI-H23 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method
    		[PMID: 35302779]
    NCI-H23 IC50
    0.49 μM
    Compound: Adriamycin
    Anti-proliferative activity against human NCI-H23 cells by XTT assay
    Anti-proliferative activity against human NCI-H23 cells by XTT assay
    		[PMID: 25442319]
    NCI-H3255 IC50
    1.5 μM
    Compound: Adriamycin
    Cytotoxicity against human NCI-H3255 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human NCI-H3255 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 34797067]
    NCI-H358 IC50
    < 5 μM
    Compound: Adriamycin
    Antiproliferative activity against human NCI-H358 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    Antiproliferative activity against human NCI-H358 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    		[PMID: 35586422]
    NCI-H446 IC50
    1.7 μM
    Compound: Adriamycin
    Cytotoxicity against human NCI-H446 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human NCI-H446 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 34797067]
    NCI-H460 IC50
    0.24 μM
    Compound: adriamycin
    Cytotoxic activity against human H460 cells by MTT method
    Cytotoxic activity against human H460 cells by MTT method
    		[PMID: 25739048]
    NCI-H460 IC50
    0.98 μM
    Compound: Adriamycin
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 26933756]
    NCI-H460 IC50
    1 μM
    Compound: Adriamycin
    Cytotoxicity against human NCI-H460 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human NCI-H460 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay
    		[PMID: 28206772]
    NCI-N87 IC50
    0.71 μM
    Compound: Adriamycin
    Cytotoxicity against human NCI-N87 cells assessed as reduction in cell growth after 72 hrs by CCK8 assay
    Cytotoxicity against human NCI-N87 cells assessed as reduction in cell growth after 72 hrs by CCK8 assay
    		[PMID: 27484510]
    NIH3T3 IC50
    0.34 μM
    Compound: ADR
    Cytotoxicity against mouse 3T3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against mouse 3T3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31977207]
    NIH3T3 IC50
    0.36 μM
    Compound: ADR
    Cytotoxicity against mouse 3T3 cells measured after 72 hrs by MTT assay
    Cytotoxicity against mouse 3T3 cells measured after 72 hrs by MTT assay
    		[PMID: 30739826]
    NIH3T3 IC50
    1.08 μM
    Compound: DOX
    Cytotoxicity against BALB mouse 3T3 cells after 72 hrs by SRB assay
    Cytotoxicity against BALB mouse 3T3 cells after 72 hrs by SRB assay
    		[PMID: 22574992]
    NUGC-3 GI50
    0.07 μM
    Compound: Adriamycin
    Cytotoxicity against human NUGC3 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human NUGC3 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay
    		[PMID: 29878761]
    NUGC-3 GI50
    0.08 μM
    Compound: Adriamycin
    Growth inhibition of human NUGC-3 cells by SRB assay
    Growth inhibition of human NUGC-3 cells by SRB assay
    		[PMID: 36040099]
    NUGC-3 IC50
    0.15 μM
    Compound: ADR
    Cytotoxicity against human NUGC-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method
    Cytotoxicity against human NUGC-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method
    		[PMID: 35302779]
    NUGC-3 GI50
    0.15 μM
    Compound: ADR
    Cytotoxicity against human NUGC3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Cytotoxicity against human NUGC3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 31668073]
    NUGC-3 IC50
    0.38 μM
    Compound: Adriamycin
    Anti-proliferative activity against human NUGC3 cells by XTT assay
    Anti-proliferative activity against human NUGC3 cells by XTT assay
    		[PMID: 25442319]
    OS-RC-2 IC50
    < 1 μM
    Compound: Adriamycin
    Cytotoxicity against human OS-RC2 cells by MTT assay
    Cytotoxicity against human OS-RC2 cells by MTT assay
    		[PMID: 20627721]
    OS-RC-2 IC50
    < 1.3 μM
    Compound: Adriamycin
    Cytotoxicity against human OS-RC2 cells by MTT assay
    Cytotoxicity against human OS-RC2 cells by MTT assay
    		[PMID: 21875764]
    OVCAR-3 GI50
    < 0.1 μM
    Compound: Adriamycin
    Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition by sulforhodamine B assay
    Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition by sulforhodamine B assay
    		[PMID: 35694689]
    OVCAR-8 GI50
    0.15 μM
    Compound: ADR
    Cytotoxicity against human OVCAR8 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human OVCAR8 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21194809]
    P388 IC50
    0.3 μM
    Compound: Adriamycin
    Cytotoxicity against mouse p388 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against mouse p388 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 33301677]
    PANC-1 GI50
    0.24 μM
    Compound: DOX HCl
    Growth inhibition against human PANC1 cells after 72 hrs by inverted microscopy
    Growth inhibition against human PANC1 cells after 72 hrs by inverted microscopy
    		[PMID: 23353738]
    PANC-1 IC50
    0.48 μM
    Compound: Adriamycin
    Cytotoxicity against human PANC1 cells after 72 hrs under normoxic condition by MTT assay
    Cytotoxicity against human PANC1 cells after 72 hrs under normoxic condition by MTT assay
    		[PMID: 29656202]
    PANC-1 IC50
    0.9 μM
    Compound: ADM
    Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    		[PMID: 35380848]
    PANC-1 IC50
    1.7 μM
    Compound: Adriamycin
    Cytotoxicity against human PANC1 cells after 72 hrs under hypoxic condition by MTT assay
    Cytotoxicity against human PANC1 cells after 72 hrs under hypoxic condition by MTT assay
    		[PMID: 29656202]
    PANC-1 IC50
    2.11 μM
    Compound: ADR
    Antiproliferative activity against human PANC1 cells after 72 hrs by MTT assay
    Antiproliferative activity against human PANC1 cells after 72 hrs by MTT assay
    		[PMID: 30006167]
    PC-3 GI50
    < 0.1 μM
    Compound: Adriamycin
    Anticancer activity against human PC-3 cells assessed as cell growth inhibition by sulforhodamine B assay
    Anticancer activity against human PC-3 cells assessed as cell growth inhibition by sulforhodamine B assay
    		[PMID: 35694689]
    PC-3 IC50
    < 1 μM
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    		[PMID: 28757067]
    PC-3 IC50
    0.02 μM
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    		[PMID: 25259515]
    PC-3 IC50
    0.09 μM
    Compound: ADR
    Cytotoxicity against human PC3 cells by colorimetric method
    Cytotoxicity against human PC3 cells by colorimetric method
    		[PMID: 32916298]
    PC-3 GI50
    0.09 μM
    Compound: Adriamycin
    Growth inhibition of human PC-3 cells by SRB assay
    Growth inhibition of human PC-3 cells by SRB assay
    		[PMID: 36040099]
    PC-3 GI50
    0.09 μM
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay
    		[PMID: 29878761]
    PC-3 GI50
    0.14 μM
    Compound: ADR
    Cytotoxicity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Cytotoxicity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 31668073]
    PC-3 IC50
    0.16 μM
    Compound: ADR
    Cytotoxicity against human PC-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method
    Cytotoxicity against human PC-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method
    		[PMID: 35302779]
    PC-3 GI50
    0.16 μM
    Compound: ADR
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    		[PMID: 20554354]
    PC-3 GI50
    0.16 μM
    Compound: ADR
    Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21194809]
    PC-3 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human PC-3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 34282909]
    PC-3 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability by SRB assay
    		[PMID: 32840364]
    PC-3 IC50
    0.38 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33774342]
    PC-3 IC50
    0.4 μM
    Compound: Adriamycin
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 34797067]
    PC-3 IC50
    0.4 μM
    Compound: Adriamycin
    Cytotoxicity against human PC-3 cells assessed as cell viability inhibition for 48 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as cell viability inhibition for 48 hrs by MTT assay
    		[PMID: 33913326]
    PC-3 IC50
    0.4 μM
    Compound: ADR
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 35762988]
    PC-3 IC50
    0.42 μM
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 29215886]
    PC-3 IC50
    0.5 μM
    Compound: Adriamycin
    Anti-proliferative activity against human PC3 cells by XTT assay
    Anti-proliferative activity against human PC3 cells by XTT assay
    		[PMID: 25442319]
    PC-3 IC50
    0.68 μM
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 21123066]
    PC-3 IC50
    0.8 μM
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells after 24 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 24 hrs by MTT assay
    		[PMID: 30049584]
    PC-3 IC50
    0.8 μM
    Compound: ADM
    Growth inhibition of human PC3 cells after 72 hrs by MTT assay
    Growth inhibition of human PC3 cells after 72 hrs by MTT assay
    		[PMID: 25064351]
    PC-3 IC50
    1 μM
    Compound: ADM
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 29985604]
    PC-3 GI50
    1.1 μM
    Compound: Doxorubicin hydrochloride
    Growth inhibition of human PC3 cells by colorimetric MTT assay
    Growth inhibition of human PC3 cells by colorimetric MTT assay
    		[PMID: 25736997]
    PC-3 IC50
    1.18 μM
    Compound: Dox
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 22318158]
    PC-3 GI50
    1.81 μM
    Compound: ADR
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    		[PMID: 20444601]
    PC-3 GI50
    1.81 μM
    Compound: ADR
    Cytotoxicity against human PC3 cells by sulforhodamine B method
    Cytotoxicity against human PC3 cells by sulforhodamine B method
    		[PMID: 21459581]
    PC-3 IC50
    11.74 μM
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells after 24 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 24 hrs by MTT assay
    		[PMID: 25226363]
    PC-3 IC50
    15.17 μM
    Compound: Adriamycin
    Cytotoxicity against docetaxel-resistant human PC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against docetaxel-resistant human PC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 27318123]
    PC-3 IC50
    16.89 μM
    Compound: Adriamycin
    Antiproliferative activity against paclitaxel-resistant human PC3 cells after 48 hrs by MTT assay
    Antiproliferative activity against paclitaxel-resistant human PC3 cells after 48 hrs by MTT assay
    		[PMID: 28222318]
    PLC-PRF-5 IC50
    1.9 μM
    Compound: Adriamycin
    Cytotoxicity against human PLC/PRF/5 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human PLC/PRF/5 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31013087]
    QG-56 IC50
    2.5 μM
    Compound: Adriamycin
    Cytotoxicity against human QG56 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human QG56 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 27318975]
    QG-56 IC50
    2.5 μM
    Compound: Adriamycin
    Cytotoxicity against human QG56 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human QG56 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 26810315]
    SAOS-2 IC50
    4.2 μM
    Compound: Adriamycin
    Growth inhibition of human Saos2 cells by MTT method
    Growth inhibition of human Saos2 cells by MTT method
    		[PMID: 25611131]
    SF-126 IC50
    0.26 μM
    Compound: ADR
    Antiproliferative activity against human SF126 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human SF126 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31977207]
    SGC-7901 IC50
    0.078 μg/mL
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human SGC7901 cells assessed as cell mortality after 20 hrs by MTT assay
    Cytotoxicity against human SGC7901 cells assessed as cell mortality after 20 hrs by MTT assay
    		[PMID: 21296573]
    SGC-7901 IC50
    0.078 μg/mL
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human SGC7901 cells after 20 hrs by MTT assay
    Cytotoxicity against human SGC7901 cells after 20 hrs by MTT assay
    		[PMID: 21247667]
    SGC-7901 IC50
    0.72 μM
    Compound: Adriamycin
    Anticancer activity against human SGC-7901 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    Anticancer activity against human SGC-7901 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    		[PMID: 35367708]
    SGC-7901 IC50
    4.12 μM
    Compound: ADM
    Antiproliferative activity against human SGC7901 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SGC7901 cells after 72 hrs by MTT assay
    		[PMID: 29232583]
    SH-SY5Y IC50
    0.1 μM
    Compound: ADM
    Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay
    Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay
    		[PMID: 29985604]
    SH-SY5Y IC50
    0.1 μM
    Compound: Adriamycin
    Cytotoxicity against human SH-SY5Y cells after 24 hrs by SRB method
    Cytotoxicity against human SH-SY5Y cells after 24 hrs by SRB method
    		[PMID: 31904949]
    SH-SY5Y IC50
    0.5 μM
    Compound: Adriamycin
    Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability by SRB assay
    		[PMID: 32840364]
    SiHa GI50
    0.15 μM
    Compound: ADR
    Cytotoxicity against human SiHa cells after 48 hrs by SRB assay
    Cytotoxicity against human SiHa cells after 48 hrs by SRB assay
    		[PMID: 20554354]
    SiHa GI50
    0.17 μM
    Compound: ADR
    Cytotoxicity against human SiHa cells after 48 hrs by SRB assay
    Cytotoxicity against human SiHa cells after 48 hrs by SRB assay
    		[PMID: 20444601]
    SiHa GI50
    0.17 μM
    Compound: ADR
    Cytotoxicity against human SiHa cells by sulforhodamine B method
    Cytotoxicity against human SiHa cells by sulforhodamine B method
    		[PMID: 21459581]
    SiHa GI50
    1.9 μM
    Compound: ADR
    Anticancer activity against human SiHa cells after 48 hrs by SRB assay
    Anticancer activity against human SiHa cells after 48 hrs by SRB assay
    		[PMID: 20557981]
    SK-BR-3 GI50
    65.5 nM
    Compound: Doxorubicin HCl
    Growth inhibition of human SKBR3 cells after 72 hrs by SRB assay
    Growth inhibition of human SKBR3 cells after 72 hrs by SRB assay
    		[PMID: 22607205]
    SMMC-7721 IC50
    0.46 μM
    Compound: Adriamycin
    Anticancer activity against human SMMC-7721 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    Anticancer activity against human SMMC-7721 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    		[PMID: 35367708]
    SMMC-7721 IC50
    0.66 μM
    Compound: Adriamycin
    Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 29215886]
    SMMC-7721 IC50
    0.8 μM
    Compound: Adriamycin
    Cytotoxicity in human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31268321]
    SMMC-7721 IC50
    0.8 μM
    Compound: Adriamycin
    Cytotoxicity in human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31117521]
    SMMC-7721 IC50
    1.1 μM
    Compound: Adriamycin
    Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31013087]
    SMMC-7721 IC50
    2.2 μM
    Compound: Adriamycin
    Cytotoxicity against human SMMC7721 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay
    		[PMID: 28206772]
    SMMC-7721 IC50
    2.24 μM
    Compound: Adriamycin
    Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 26933756]
    SMMC-7721 IC50
    2.67 μM
    Compound: ADM
    Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 30739827]
    SMMC-7721 IC50
    2.67 μM
    Compound: ADM
    Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay
    		[PMID: 29232583]
    SNU1 IC50
    2.01 μM
    Compound: Adriamycin
    Anticancer activity against human SNU1 cells assessed as reduction in cell viability for 72 hrs by MTT assay
    Anticancer activity against human SNU1 cells assessed as reduction in cell viability for 72 hrs by MTT assay
    		[PMID: 35367708]
    SU.86.86 IC50
    0.33 μM
    Compound: Adriamycin
    Cytotoxicity against human SU-86-86 cells assessed as inhibition of cell growth by CCK-8 assay
    Cytotoxicity against human SU-86-86 cells assessed as inhibition of cell growth by CCK-8 assay
    		[PMID: 36583957]
    SW-620 IC50
    < 5 μM
    Compound: Adriamycin
    Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    		[PMID: 35586422]
    SW-620 IC50
    0.09 μM
    Compound: ADR
    Cytotoxicity against human SW620 cells by colorimetric method
    Cytotoxicity against human SW620 cells by colorimetric method
    		[PMID: 32916298]
    SW-620 IC50
    1.2 μM
    Compound: Adriamycin
    Cytotoxicity in human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31268321]
    T47D IC50
    0.04 μM
    Compound: ADM
    Antiproliferative activity against human T47D cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay
    Antiproliferative activity against human T47D cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay
    		[PMID: 26866967]
    T47D IC50
    0.25 μM
    Compound: Adriamycin
    Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
    		[PMID: 28384547]
    T47D IC50
    0.3 μM
    Compound: Adriamycin
    Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
    		[PMID: 28068603]
    T47D IC50
    0.31 μM
    Compound: Adriamycin
    Antiproliferative activity against human T47D cells incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human T47D cells incubated for 72 hrs by CCK8 assay
    		[PMID: 29402741]
    T47D IC50
    0.31 μM
    Compound: Adriamycin
    Antiproliferative activity against human T47D cells after 72 hrs by EZ-CYTOX reagent based assay
    Antiproliferative activity against human T47D cells after 72 hrs by EZ-CYTOX reagent based assay
    		[PMID: 30262132]
    T47D IC50
    0.34 μM
    Compound: Adriamycin
    Antiproliferative activity against human T47D cells measured after 72 hrs by EZ-Cytox assay
    Antiproliferative activity against human T47D cells measured after 72 hrs by EZ-Cytox assay
    		[PMID: 31398033]
    T47D IC50
    0.41 μM
    Compound: Adriamycin
    Cytotoxicity against human T47D cells incubated from day 2 to day 4 by CCK8 assay
    Cytotoxicity against human T47D cells incubated from day 2 to day 4 by CCK8 assay
    		[PMID: 26022080]
    T47D IC50
    0.84 μM
    Compound: Adriamycin
    Antiproliferative activity against human T47D cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human T47D cells after 72 hrs by CCK-8 assay
    		[PMID: 29510948]
    T47D IC50
    0.84 μM
    Compound: ADM
    Cytotoxicity against human T47D cells after 72 hrs by cell counting kit-8 analysis
    Cytotoxicity against human T47D cells after 72 hrs by cell counting kit-8 analysis
    		[PMID: 29174815]
    T47D IC50
    1.29 μM
    Compound: Adriamycin
    Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
    		[PMID: 28633898]
    T47D IC50
    1.34 μM
    Compound: Adriamycin
    Cytotoxicity against human T47D cells after 3 days by CCK8 assay
    Cytotoxicity against human T47D cells after 3 days by CCK8 assay
    		[PMID: 26927425]
    T47D IC50
    1.34 μM
    Compound: Adriamycin
    Cytotoxicity against human T47D cells after 48 hrs by CCK8 assay
    Cytotoxicity against human T47D cells after 48 hrs by CCK8 assay
    		[PMID: 26945111]
    T47D IC50
    1.34 μM
    Compound: Adriamycin
    Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
    		[PMID: 27643560]
    T47D IC50
    1.42 μM
    Compound: Adriamycin
    Cytotoxicity against human T47D cells assessed as reduction in cell growth after 72 hrs by CCK8 assay
    Cytotoxicity against human T47D cells assessed as reduction in cell growth after 72 hrs by CCK8 assay
    		[PMID: 27484510]
    T47D IC50
    1.48 μM
    Compound: Adriamycin
    Antiproliferative activity against human T47D cells after 72 hrs by EZ-Cytox colorimetric assay
    Antiproliferative activity against human T47D cells after 72 hrs by EZ-Cytox colorimetric assay
    		[PMID: 34678573]
    T47D IC50
    1.5 μM
    Compound: Adriamycin
    Antiproliferative activity against human T47D cells measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human T47D cells measured after 72 hrs by CCK8 assay
    		[PMID: 27654394]
    T47D IC50
    2.18 μM
    Compound: Adriamycin
    Cytotoxicity against human T47D cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay
    Cytotoxicity against human T47D cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay
    		[PMID: 27707625]
    T47D IC50
    2.9 μM
    Compound: Adriamycin
    Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
    		[PMID: 26988802]
    T47D IC50
    3.12 μM
    Compound: Adriamycin
    Cytotoxicity against human T47D cells after 4 days by CCK-8 assay
    Cytotoxicity against human T47D cells after 4 days by CCK-8 assay
    		[PMID: 25062006]
    THP-1 IC50
    0.02 μM
    Compound: Adriamycin
    Cytotoxicity against human THP1 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human THP1 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay
    		10.1039/C5MD00289C
    U-118-MG IC50
    0.09 μM
    Compound: ADR
    Antiproliferative activity against human U118MG cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human U118MG cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31977207]
    U-251 IC50
    0.157 μM
    Compound: Adriamycin
    Cytotoxicity against human U251 cells assessed as inhibition of proliferation incubated for 72 hrs by MTT assay
    Cytotoxicity against human U251 cells assessed as inhibition of proliferation incubated for 72 hrs by MTT assay
    		[PMID: 34237623]
    U-251 IC50
    2.8 μM
    Compound: Adriamycin
    Cytotoxicity in human U251 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human U251 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31268321]
    U-251 IC50
    2.9 μM
    Compound: Adriamycin
    Cytotoxicity in human U251 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human U251 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31117521]
    U-251 IC50
    48 μM
    Compound: ADR
    Antiproliferative activity against human U251 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human U251 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31977207]
    U-87MG ATCC IC50
    0.1 μM
    Compound: Adriamycin
    Cytotoxicity against human U87 cells after 24 hrs by SRB method
    Cytotoxicity against human U87 cells after 24 hrs by SRB method
    		[PMID: 31904949]
    U-87MG ATCC IC50
    0.11 μM
    Compound: Doxorubicin.HCl
    Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 30223117]
    U-87MG ATCC IC50
    0.15 μM
    Compound: ADR
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31977207]
    U-87MG ATCC IC50
    0.16 μM
    Compound: ADR
    Antiproliferative activity against human U87 cells after 72 hrs by MTT assay
    Antiproliferative activity against human U87 cells after 72 hrs by MTT assay
    		[PMID: 30006167]
    U-87MG ATCC IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human U87 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human U87 cells assessed as reduction in cell viability by SRB assay
    		[PMID: 32840364]
    U-87MG ATCC IC50
    0.57 μM
    Compound: Adriamycin
    Anticancer activity against human U87 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    Anticancer activity against human U87 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    		[PMID: 35367708]
    U-87MG ATCC IC50
    1.1 μM
    Compound: Adriamycin
    Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31117521]
    U-87MG ATCC IC50
    4.28 μM
    Compound: ADM
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 30739827]
    UACC-62 GI50
    0.25 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human UACC62 cells assessed as growth inhibition by SRB assay
    Cytotoxicity against human UACC62 cells assessed as growth inhibition by SRB assay
    		[PMID: 24507920]
    Vero GI50
    0.02 μM
    Compound: ADR
    Cytotoxicity against African green monkey Vero cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against African green monkey Vero cells after 72 hrs by sulforhodamine B assay
    		[PMID: 28778369]
    Vero GI50
    19 μM
    Compound: Adriamycin
    Cytotoxicity against African green monkey Vero cells after 48 hrs by SRB assay
    Cytotoxicity against African green monkey Vero cells after 48 hrs by SRB assay
    		[PMID: 28258796]
    Vero GI50
    2 μM
    Compound: ADR
    Cytotoxicity against African green monkey Vero cells assessed as total inhibition of cell growth after 72 hrs by sulforhodamine B assay
    Cytotoxicity against African green monkey Vero cells assessed as total inhibition of cell growth after 72 hrs by sulforhodamine B assay
    		[PMID: 28778369]
    WI-38 IC50
    0.08 μM
    Compound: Adriamycin
    Cytotoxicity against human WI38 cells after 72 hrs by CCK8 assay
    Cytotoxicity against human WI38 cells after 72 hrs by CCK8 assay
    		[PMID: 27997206]
    YAPC IC50
    0.31 μM
    Compound: Adriamycin
    Cytotoxicity against human YAPC cells assessed as inhibition of cell growth by CCK-8 assay
    Cytotoxicity against human YAPC cells assessed as inhibition of cell growth by CCK-8 assay
    		[PMID: 36583957]
    ZR-75-1 GI50
    < 0.1 μM
    Compound: ADR
    Anticancer activity against human ZR-75-1 cells after 48 hrs by SRB assay
    Anticancer activity against human ZR-75-1 cells after 48 hrs by SRB assay
    		[PMID: 20557981]
    ZR-75-1 GI50
    0.12 μM
    Compound: ADR
    Cytotoxicity against human ZR-75-1 cells after 48 hrs by SRB assay
    Cytotoxicity against human ZR-75-1 cells after 48 hrs by SRB assay
    		[PMID: 20554354]
    ZR-75-1 GI50
    1.79 μM
    Compound: ADR
    Cytotoxicity against human ZR-75-1 cells after 48 hrs by SRB assay
    Cytotoxicity against human ZR-75-1 cells after 48 hrs by SRB assay
    		[PMID: 20444601]
    ZR-75-1 GI50
    1.79 μM
    Compound: ADR
    Cytotoxicity against human ZR-75-1 cells by sulforhodamine B method
    Cytotoxicity against human ZR-75-1 cells by sulforhodamine B method
    		[PMID: 21459581]
    In Vitro

    Doxorubicin hydrochloride (1-8 μM; 24 and 48 hours) decreases the viability of MCF-10F, MCF-7 and MDA-MB-231 cells in a time- and dose-dependent manner[4].
    Doxorubicin hydrochloride (1 μM; 3 and 24 hours) results in Hct-116 human colon carcinoma cells reduction in G0/G1 phase and accumulation in G2 phase[5].
    Doxorubicin hydrochloride (1 μM for MCF-10F and MDA-MB-231 cells, 4 μM for MCF-7 cells; 48 hours) induces apoptosis by upregulating Bax, caspase-8 and caspase-3 and downregulation of Bcl-2 protein expression[4].
    Doxorubicin hydrochloride (5 μM; 10-30 min) can be accumulated in B16-F10 melanoma cell line CRL-6475 in a time-dependent manner, and can be detected by green or red fluorescence (green fluorescence has higher detection sensitivity) with a maximum excitation wavelength (λex) and a maximum emission wavelength (λem) of 470 nm and 560 nm, respectively[8].
    Note:
    Doxorubicin hydrochloride is suitable for neutral or weakly acidic solvents; PBS (PH 7.4) is not recommended for dissolution, which may affect the dissolution effect.

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Doxorubicin hydrochloride Related Antibodies

    Cell Viability Assay[4]

    Cell Line: Breast cancer cell lines MCF-10F, MCF-7 and MDA-MB-231
    Concentration: 0, 1, 2, 4 and 8 μM
    Incubation Time: 24 and 48 hours
    Result: IC50 was 1 μM for both MCF-10F and MDA-MB-231 cell lines.
    IC50 was 4 μM for MCF-7 cell line.

    Cell Cycle Analysis[5]

    Cell Line: Hct-116 human colon carcinoma cells
    Concentration: 1 μM
    Incubation Time: 3 hours and 24 hours
    Result: Both, bolus (3 h) and continuous (24 h) incubation led to a significant reduction of cells in G0/G1 and accumulation in G2 phase.

    Western Blot Analysis[4]

    Cell Line: Breast cancer cell lines MCF-10F, MCF-7 and MDA-MB-231
    Concentration: 1 μM for MCF-10F and MDA-MB-231 cells, 4 μM for MCF-7 cells
    Incubation Time: 48 hours
    Result: Bax protein expression was upregulated in MCF-10F and MDA-MB-231 cell lines but MCF-7 cells did not show any significant increase.
    Caspase-8 gene expression was upregulated in MCF-10F, but it was downregulated in MCF-7 and MDA-MB-231 cells.
    In Vivo

    Doxorubicin hydrochloride can be used to induce models of cardiotoxicity and heart failure.

    1. Inducing cardiotoxicity[10][11]
    Background
    The mechanism of short-term induction of cardiotoxicity: promoting extracellular remodeling of myocardium to induce heart failure, and also works at the molecular level. Including: interacting with iron, changing the activity of oxidases in cells or mitochondria, and binding to topoisomerases.
    Specific Mmodeling Methods
    Mice: Female C57BL/6j mice • 20-22 g • 6 weeks old
    Administration: 2 mg/kg, 10 mg/kg • ip • once every the other day for 2 or 3 times
    Note
    Mice were sacrificed 3 days after the first injection.
    Modeling Indicators
    molecular level: (1) Pro-inflammatory cytokines (such as TNF-α and IL-6) increase significantly, while anti-inflammatory cytokine IL-10 decreases; (2) Inducible - Nitric oxide synthase (iNOS) was overexpressed and serum nitrite levels were elevated; nitrotyrosine expression was significantly increased.
    Correlated Product(s): /
    Opposite Product(s): /

    2. Induction of heart failure[11][12]
    Background
    The long-term mechanisms inducing heart failure remain to be carefully elucidated.
    Specific Mmodeling Methods
    Rat: Male Wistar rats • 180-200 g
    Administration: 2.5 mg/kg • ip • once every week, for 6 weeks • treated at 4 weeks later.
    Note
    Modeling Indicators
    Cellular/tissue level: Myocardial sarcomeres are destroyed, mitochondria are swollen and damaged, Myocardial cells showed inflammation and apoptosis (transmission electron microscopy results); myocardial fibrosis, and left ventricular collagen I and II levels were downregulated (immunohistochemistry results).
    Changes in macroscopic indicators: Hemodynamic parameters and echocardiography show cardiac insufficiency and impaired left ventricular function; such as increases in LVIDd, LVIDs and LVEDP.
    Correlated Product(s): /
    Opposite Product(s): Captopril (HY-B0368)

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Female MF1 nu/nu mice bearing MDA-G8 breast tumor xenograft (6-week-old)[6]
    Dosage: Doxorubicin (2 mg/kg); Zoledronic acid (100 μg/kg)
    Administration: Intravenous injection; once a week; 6 weeks
    Result: Moderate inhibition of subcutaneous tumor growth in mice that were treated with 2 mg/kg Doxorubicin alone or with 100 μg/kg Zoledronic acid alone compared to the saline control.
    Mice treated with Zoledronic acid and Doxorubicin together had statistically significant smaller mean tumor volumes on day 42 than those treated with Doxorubicin alone.
    Animal Model: Male Sprague-Dawley rats[7]
    Dosage: 1%, 2%, 4%, 5%, 6%, 10%, 20%
    Administration: Intrastriatal injection; Single dose
    Result: In doses of 4, 5, 6, 10 or 20% caused obvious loss of ipsilateral SNc and VTA neuronsz and doses of 1 or 2% failed to produce obvious neuron loss.
    Essai clinique
    Masse moléculaire

    579.98

    Formule

    C27H30ClNO11
    CAS No.

    25316-40-9
    Appearance

    Solid

    Color

    Red to orange

    SMILES

    COC1=C2C(C(C(C(O)=C(C[C@](C(CO)=O)(O)C[C@@H]3O[C@@]4(12)C[C@H](N)[C@H](O)[C@H](C)O4)C3=C5O)=C5C2=O)=O)=CC=C1.12Cl
    Structure Classification
    • Quinones
    • Anthraquinones
    Initial Source
    • Microorganisms

    Streptomyces peucetius var. Caesius
    Livraison

    Room temperature in continental US; may vary elsewhere.
    Stockage

    4°C, sealed storage, away from moisture and light

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

    Solvant et solubilité
    In Vitro: 

    H2O : 50 mg/mL (86.21 mM; ultrasonic and warming and heat to 60°C)

    DMSO : 25 mg/mL (43.10 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.7242 mL 8.6210 mL 17.2420 mL
    5 mM 0.3448 mL 1.7242 mL 3.4484 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Calculateur de molarité

    • Calculateur de dilution

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  5% DMSO    40% PEG300    5% Tween-80    50% Saline

      Solubility: ≥ 2.75 mg/mL (4.74 mM); Clear solution

    • Protocol 2

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (3.59 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  Saline

      Solubility: 8.33 mg/mL (14.36 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Pureté et documentation

    Purity: 99.90%

    SDS (557 KB)

    COA (258 KB) HNMR (287 KB) RP-HPLC (244 KB) LCMS (94 KB)

    Instruction de manipulation (2659 KB)
    Références

    • [1]. John L. Nitiss, et al. Targeting DNA topoisomerase II in cancer chemotherapy.Nat Rev Cancer. 2009 May;9(5):338-50.  [Content Brief]

      [2]. Hee-KyungRhee,et al. Synthesis, cytotoxicity, and DNA topoisomerase II inhibitory activity of benzofuroquinolinediones. Bioorg Med Chem. 2007 Feb 15;15(4):1651-8.  [Content Brief]

      [3]. P D Foglesong, et al. Doxorubicin inhibits human DNA topoisomerase I. Cancer Chemother Pharmacol. 1992;30(2):123-5.  [Content Brief]

      [4]. Nesstor Pilco-Ferreto, et al. Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines. Int J Oncol. 2016 Aug;49(2):753-62.  [Content Brief]

      [5]. Regine Lüpertz, et al. Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells. Toxicology. 2010 May 27;271(3):115-21.  [Content Brief]

      [6]. Penelope D Ottewell, et al. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78.  [Content Brief]

      [7]. Koda LY, Van der Kooy D. Doxorubicin: a fluorescent neurotoxin retrogradely transported in the central nervous system. Neurosci Lett. 1983 Mar 28;36(1):1-8. doi: 10.1016/0304-3940(83)90476-7. PMID: 6190113. 9  [Content Brief]

      [8]. Kauffman MK, Kauffman ME, Zhu H, Jia Z, Li YR. Fluorescence-Based Assays for Measuring Doxorubicin in Biological Systems. React Oxyg Species (Apex). 2016;2(6):432-439. doi: 10.20455/ros.2016.873. PMID: 29707647; PMCID: PMC5921830.  [Content Brief]

      [9]. Mirza A Z, Shamshad H. Preparation and characterization of doxorubicin functionalized gold nanoparticles[J]. European journal of medicinal chemistry, 2011, 46(5): 1857-1860.

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO / H2O 1 mM 1.7242 mL 8.6210 mL 17.2420 mL 43.1049 mL
    5 mM 0.3448 mL 1.7242 mL 3.4484 mL 8.6210 mL
    10 mM 0.1724 mL 0.8621 mL 1.7242 mL 4.3105 mL
    15 mM 0.1149 mL 0.5747 mL 1.1495 mL 2.8737 mL
    20 mM 0.0862 mL 0.4310 mL 0.8621 mL 2.1552 mL
    25 mM 0.0690 mL 0.3448 mL 0.6897 mL 1.7242 mL
    30 mM 0.0575 mL 0.2874 mL 0.5747 mL 1.4368 mL
    40 mM 0.0431 mL 0.2155 mL 0.4310 mL 1.0776 mL
    H2O 50 mM 0.0345 mL 0.1724 mL 0.3448 mL 0.8621 mL
    60 mM 0.0287 mL 0.1437 mL 0.2874 mL 0.7184 mL
    80 mM 0.0216 mL 0.1078 mL 0.2155 mL 0.5388 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Doxorubicin hydrochloride Related Classifications

    Help & FAQs

    Keywords:

    Doxorubicin25316-40-9Hydroxydaunorubicin ADRTopoisomeraseADC CytotoxinAMPKAutophagyApoptosisHIVHBVMitophagyAntibioticBacterialADC PayloadAMP-activated protein kinaseHuman immunodeficiency virusHepatitis B virusMitochondrial AutophagyCardiotoxicityNeurotoxicityfluorescenceHelaCRL-6475fluorescence detectionantibioticstumorapoptosisautophagyInhibitorinhibitorinhibit

    Si può anche essere interessati nei seguenti prodotti:



    Cat#
    Descrizione
    Cond.
    Priced
    6200-SC
    Cardiac Myocytes
     1x10^6cells/vial 
    AAM-INF-1-8
    Mouse Inflammation Array C1
     8SampleKit